<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0301244663
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREVENAR 20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        POLYSACCHARIDE FOR SEROTYPES 1, 3, 4, 5, 6A, 7F, 8, 9V, 10, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F,POLYSACCHARIDE FOR SEROTYPES 6B,CRM197 protein
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.2,4.4,51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2704.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Ireland Pharmaceuticals" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Ireland Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AL02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prevenar&nbsp;20 is a pneumococcal vaccine given to:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>children from 6&nbsp;weeks to less than 18&nbsp;years of age</strong> to help prevent diseases such as meningitis (inflammation around the brain), sepsis or bacteraemia (bacteria in the blood stream), pneumonia (lung infection) and ear infections (acute otitis media) caused by 20 types of the bacteria <em>Streptococcus pneumoniae</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>individuals aged 18&nbsp;years and older</strong> to help prevent disease such as: pneumonia (lung infection), sepsis or bacteraemia (bacteria in the blood stream) and meningitis (inflammation around the brain) caused by 20 types of the bacteria <em>Streptococcus pneumoniae.</em></p><p>&nbsp;</p><p>Prevenar&nbsp;20 provides protection against 20 types of <em>Streptococcus pneumoniae</em> bacteria.</p><p>&nbsp;</p><p>The vaccine works by helping the body to make its own antibodies, which protect you or your child against these diseases.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Prevenar&nbsp;20</strong><strong> should not be given</strong></p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or your child are allergic (hypersensitive) to the active substances or to any of the other ingredients in this medicine (listed in section&nbsp;6), or to any other vaccine that contains diphtheria toxoid.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor, pharmacist or nurse before the vaccination if you or your child:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have any present or past medical problems after any dose of Prevenar&nbsp;20 such as an allergic reaction or problems with breathing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a severe illness or high fever. However, a mild fever or upper respiratory infection (for example having a cold) itself is not a reason to delay vaccination,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have any bleeding problems or bruise easily,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a weakened immune system (such as due to HIV infection); you may not get the full benefit from Prevenar&nbsp;20.</p><p>&nbsp;</p><p>Talk to your doctor, pharmacist, or nurse before the vaccination if your child was born very prematurely (at or before 28&nbsp;weeks of gestation), as longer gaps than normal between breaths may occur for 2‑3 days after vaccination.</p><p>&nbsp;</p><p>As with any vaccine, Prevenar&nbsp;20 will not protect all persons who are vaccinated.</p><p>&nbsp;</p><p>Prevenar&nbsp;20 will only protect against ear infections caused by the types of <em>Streptococcus</em> <em>pneumoniae </em>for which the vaccine has been developed. It will not protect against other infectious agents that can cause ear infections.</p><p>&nbsp;</p><p><strong>Other medicines/vaccines and Prevenar&nbsp;20</strong></p><p>Your child may be given Prevenar&nbsp;20 at the same time as other routine childhood vaccines.</p><p>&nbsp;</p><p>In adults, Prevenar&nbsp;20 may be given at the same time as the flu (inactivated influenza) vaccine at different injection sites. Depending on the individual risk assessment of your health care provider, separation of both vaccinations of e.g., 4 weeks might be advised.</p><p>&nbsp;</p><p>In adults, Prevenar&nbsp;20 can be given at the same time as the COVID-19 mRNA vaccine.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you or your child are taking, have recently taken or might take any other medicines, or have recently received any other vaccine.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before receiving this vaccine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Prevenar&nbsp;20 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section&nbsp;4 &ldquo;Possible side effects&rdquo; may temporarily affect the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Prevenar&nbsp;20</strong> <strong>contains sodium</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor or nurse will inject the recommended dose (0.5&nbsp;mL) of the vaccine into your upper arm or your child&#39;s upper arm or thigh muscle.</p><p>&nbsp;</p><p><u>Infants 6&nbsp;weeks to 15&nbsp;months of age</u></p><p><u>&nbsp;</u></p><p>Your child should receive an initial course of three injections of the vaccine followed by a booster dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first injection may be given as early as 6&nbsp;weeks to 8&nbsp;weeks of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each injection will be given on a separate occasion with an interval of at least 4 weeks between doses except for the last injection (booster dose), which will be given between 11 and 15&nbsp;months of age.</p><p>You will be told when your child should come back for the next injections.</p><p>&nbsp;</p><p>Depending on official recommendations in your country, please speak to your doctor, pharmacist, or nurse for more information.</p><p>&nbsp;</p><p><u>Premature infants (born less than 37&nbsp;weeks of pregnancy)</u></p><p>&nbsp;</p><p>Your child will receive an initial course of three injections followed by a booster dose. The first injection may be given as early as 6&nbsp;weeks of age with at least 4 weeks between doses. Between 11 and 15&nbsp;months of age, your child will receive a fourth injection (booster dose).</p><p>&nbsp;</p><p><u>Unvaccinated infants <u>7&nbsp;months to less than 12&nbsp;months of age</u></u><u> </u></p><p>&nbsp;</p><p>Infants <strong>7&nbsp;months to less than 12&nbsp;months </strong>of age<strong> </strong>should receive three injections. The first two are given with an interval of at least 4&nbsp;weeks apart. A third injection will be given in the second year of life.</p><p>&nbsp;</p><p><u>Unvaccinated children 12&nbsp;months to less than </u><u>24&nbsp;months of age</u></p><p>&nbsp;</p><p>Children <strong>12&nbsp;months to less than 24&nbsp;months </strong>of age should receive two injections, given with an interval of at least 8&nbsp;weeks apart.</p><p>&nbsp;</p><p>Unvaccinated children 2&nbsp;years to less than 5&nbsp;years of age</p><p>&nbsp;</p><p>Children <strong>2&nbsp;years to less than 5&nbsp;years</strong> of age<strong> </strong>should receive one injection.</p><p>&nbsp;</p><p><u>Children 15&nbsp;months to less than 5&nbsp;years of age previously fully vaccinated with Prevenar 13</u><em><u> </u></em></p><p>&nbsp;</p><p>Children <strong>15&nbsp;months to less than 5 years</strong> of age previously fully vaccinated with Prevenar&nbsp;13 will receive one injection.</p><p>&nbsp;</p><p>Children and adolescents 5&nbsp;years to less than 18&nbsp;years of age regardless of prior Prevenar 13 vaccination</p><p>&nbsp;</p><p>Children and adolescents <strong>5 years to less than 18 years</strong> of age will receive one injection.</p><p>&nbsp;</p><p>If your child has previously received Prevenar&nbsp;13, an interval of at least 8&nbsp;weeks should pass before receiving Prevenar&nbsp;20.</p><p>&nbsp;</p><p><u>Adults</u></p><p>&nbsp;</p><p>Adults should receive one injection.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you have been given a pneumococcal vaccine before.</p><p><u>&nbsp;</u></p><p>If you have any further questions on the use of Prevenar&nbsp;20, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p>Individuals considered to be at a higher risk of pneumococcal infection (such as those with sickle cell disease or HIV infection), including those previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine, may receive at least one dose of Prevenar&nbsp;20.</p><p>&nbsp;</p><p>Individuals with a blood-forming stem cell transplant may receive three injections, with the first given at 3 to 6 months after the transplant and with an interval of at least 4 weeks between doses. A fourth injection (booster dose) is recommended 6 months after the third injection.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines, Prevenar&nbsp;20 can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects of Prevenar&nbsp;20 </strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor immediately if you notice signs of the following serious side effects (see also section&nbsp;2): swelling of the face, lips, mouth, tongue or throat (oedema), shortness of breath (dyspnoea), wheezing (bronchospasm) &ndash; these may by signs of a severe allergic reaction such as anaphylaxis, including shock.</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>The following side effects include those reported for Prevenar&nbsp;20 in infants and children (6&nbsp;weeks to less than 5&nbsp;years of age):</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common: </strong>may occur with more than 1 in 10 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site for all children: redness, hardness or swelling, pain or tenderness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site after the booster dose and in children 2 to less than 5 years of age: redness, hardness or swelling of greater than 2.0 to 7.0&nbsp;cm.</p><p>&nbsp;</p><p><strong>Common:</strong> may occur with up to 1 in 10 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (high temperature of 38.9 &deg;C or higher).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site after the initial course of injections: redness, hardness or swelling of greater than 2.0 to 7.0&nbsp;cm, pain or tenderness interfering with movement.</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may occur with up to 1 in 100 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (or fits), including those caused by a high temperature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria or urticaria-like rash).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site: redness, hardness or swelling of more than&nbsp;7.0&nbsp;cm.</p><p>&nbsp;</p><p><strong>Rare: </strong>may occur with up to 1 in 1,000 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site allergic (hypersensitivity) reaction.</p><p>&nbsp;</p><p><strong>The following side effects were seen with Prevenar&nbsp;13 and may also be seen with</strong><strong> Prevenar&nbsp;20</strong><strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collapse or shock-like state (hypotonic-hyporesponsive episode).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reaction including swelling of the face and/or lips.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crying.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restless sleep.</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;20 in children and adolescents (5 years to less than 18 years of age):</strong></p><p>&nbsp;</p><p><strong>Very common: </strong>may occur with more than 1 in 10 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site: pain, tenderness, redness, hardness or swelling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness.</p><p>&nbsp;</p><p><strong>Common: </strong>may occur with up to 1 in 10 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site: pain or tenderness interfering with movement.</p><p>&nbsp;</p><p><strong>Uncommon:</strong> may occur with up to 1 in 100 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria or urticaria-like rash).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever.</p><p>&nbsp;</p><p><strong>The following side effects were seen with Prevenar&nbsp;13 and may also be seen with</strong><strong> Prevenar&nbsp;20</strong><strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restless sleep.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&nbsp;</p><p>Children and adolescents with either HIV infection, sickle cell disease or a blood-forming stem cell transplant had similar side effects, however, the frequencies of vomiting, diarrhoea, fever, joint pain and at the injection site: pain or tenderness interfering with movement were very common.</p><p>&nbsp;</p><p><strong>The following side effects were seen with Prevenar&nbsp;13 in postmarketing experience in children and may also be seen with</strong><strong> </strong><strong>Prevenar&nbsp;20</strong><strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction including shock (cardiovascular collapse); swelling of lips, face or throat (angioedema).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination site, such as under the arm or in the groin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the injection site: hives (urticaria), redness and irritation (dermatitis) and itching (pruritus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rash causing itchy red blotches (erythema multiforme).</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;20 in adults:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common:</strong> may occur with more than 1 in 10 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain and muscle pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain/tenderness at injection site and tiredness.</p><p>&nbsp;</p><p><strong>Common:</strong> may occur up to 1 in 10 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling at injection site, redness at injection site and fever.</p><p><em>&nbsp;</em></p><p><strong>Uncommon:</strong> may occur up to 1 in 100 doses of the vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea, and vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash and swelling of the face, lips, mouth, tongue or throat, which may cause difficulty in swallowing or breathing (angioedema).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching at injection site, swollen glands in the neck, armpit or groin (lymphadenopathy), hives at the injection site (urticaria), and chills.</p><p>&nbsp;</p><p><strong>The following side effects were seen with Prevenar&nbsp;13 and may also be seen with</strong><strong> Prevenar&nbsp;20</strong><strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rash causing itchy red blotches (erythema multiforme).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation at injection site.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Limitation of arm movement.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:348px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>&nbsp;</p><p>Prevenar 20 should be used as soon as possible after being removed from refrigeration.</p><p>&nbsp;</p><p>Do not freeze. Discard if vaccine has been frozen.</p><p>&nbsp;</p><p>Stability data indicate that the vaccine is stable for 96 hours when stored at temperatures from 8&deg;C to 25&deg;C, or 72 hours when stored at temperatures from 0&deg;C to 2&deg;C. At the end of these time periods Prevenar 20 should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.</p><p>&nbsp;</p><p>Pre-filled syringes should be stored in the refrigerator horizontally to minimise the resuspension time.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are polysaccharide CRM<sub>197</sub> conjugates consisting of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2&nbsp;micrograms of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.4&nbsp;micrograms of polysaccharide for serotype 6B</p><p>&nbsp;</p><p>One dose (0.5&nbsp;mL) contains approximately 51 micrograms CRM<sub>197</sub> carrier protein, adsorbed on aluminium phosphate (0.125&nbsp;mg aluminium).</p><p>&nbsp;</p><p>The other ingredients are sodium chloride, succinic acid, polysorbate 80 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The vaccine is a white suspension for injection, provided in a single-dose, pre-filled syringe (0.5 mL). It is provided in pack sizes of 1, 10 and 50, with or without needles. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Marketing Authorisation Holder:</p><p>Pfizer Europe MA EEIG</p><p>Boulevard de la Plaine 17</p><p>1050 Bruxelles</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufactured by</strong></p><p>Pfizer Ireland Pharmaceuticals</p><p>Grange Castle Business Park, Dublin, Ireland</p><p>&nbsp;</p><p><strong>Packed &amp; Released by</strong></p><p>Pfizer Manufacturing Belgium NV</p><p>Puurs, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لقاح بريفينار ٢٠ هو لقاح المكورات الرئوية الذي يتم إعطاؤه إلى:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأطفال من عمر ٦ أسابيع وحتى </strong><strong>۱۸</strong><strong> عامًا</strong> للمساعدة في الوقاية من الإصابة بأمراض مثل: التهاب السحايا (التهاب الأغشية المحيطة بالدماغ) والإنتان أو تجرثم الدم (وجود بكتيريا في مجرى الدم) والالتهاب الرئوي (عدوى الرئة) وحالات عدوى الأذن (الالتهاب الحاد في الأذن الوسطى) التي يسببها ٢٠ نوعًا من بكتيريا المكورات العقدية الرئوية (ستربتوكوكس نيمونيا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأفراد الذين يبلغون من العمر ١٨ عامًا فأكثر</strong> للمساعدة في الوقاية من الإصابة بأمراض مثل: الالتهاب الرئوي (عدوى الرئة) والإنتان أو تجرثم الدم (وجود بكتيريا في مجرى الدم) والتهاب السحايا (التهاب الأغشية المحيطة بالدماغ)، التي يسببها ٢٠ نوعًا من بكتيريا المكورات العقدية الرئوية (ستربتوكوكس نيمونيا).</p><p>&nbsp;</p><p dir="RTL">يوفر بريفينار ٢٠ الوقاية من ٢٠ نوعًا من بكتيريا المكورات العقدية الرئوية (ستربتوكوكس نيمونيا).</p><p>&nbsp;</p><p dir="RTL">ويعمل هذا اللقاح عن طريق مساعدة الجسم على إنتاج أجسامه المضادة التي تحميك أنت أو طفلك من هذه الأمراض.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال بريفينار ٢٠</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو طفلك مصابين بالحساسية (فرط الحساسية) تجاه المواد الفعالة أو أي من المكونات الأخرى الموجودة في هذا الدواء (المدرجة في القسم ٦) أو تجاه أي لقاح آخر يحتوي على ذوفان الدفتيريا.</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال بريفينار ٢٠</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">تحدث مع الطبيب أو الصيدلي أو الممرضة قبل تلقيك أنت أو طفلك اللقاح في الحالات التالية:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو طفلك تعانيان حاليًا أو سبق أن عانيتما أي مشكلات صحية بعد تلقي أي جرعة من بريفينار ٢٠، كالإصابة بتفاعل حساسية أو مشكلات تنفسية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو طفلك تعانيان مرضًا شديدًا أو حمى مرتفعة. ومع ذلك، فإن الحمى الخفيفة أو عدوى الجهاز التنفسي العلوي (مثل الإصابة بالبرد) في حد ذاتها ليست سببًا لتأخير تلقي اللقاح،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو طفلك تعانيان مشكلات نزفية أو تصابان بالتكدم بسهولة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو طفلك تعانيان ضعف الجهاز المناعي (نتيجة لعدوى فيروس نقص المناعة البشرية HIV كمثال)، فقد لا تستفيدان بشكل كامل من لقاح بريفينار ٢٠.</p><p>&nbsp;</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تلقي اللقاح في الحالات التالية إذا وُلد طفلك قبل الأوان بفترة كبيرة (في الأسبوع رقم ٢۸ من الحمل أو قبله)، حيث قد تطول الفترة الفاصلة بين الأنفاس عن المعدل الطبيعي لمدة يومين-۳ أيام بعد تلقي اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وكما هو الحال بالنسبة لأي لقاح، فإن بريفينار ٢٠ لن يقي جميع الأشخاص الذين يتلقونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يساعد بريفينار ٢٠ فقط في الوقاية من حالات عدوى الأذن التي تسببها أنواع بكتيريا المكورات العقدية الرئوية (ستربتوكوكس نيمونيا) التي طُوِّر هذا اللقاح لمكافحتها. ولكنه لا يقي من العوامل المُعدية الأخرى التي قد تسبب حالات عدوى الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية.</strong></p><p dir="RTL">يمكن إعطاء طفلك بريفينار ٢٠ في نفس الوقت مع لقاحات مرحلة الطفولة الروتينية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للبالغين، يمكن إعطاء بريفينار ٢٠ في نفس الوقت مع لقاح الإنفلونزا (لقاح الإنفلونزا غير النشط) في مواضع حقن مختلفة. وحسب تقييم مقدم رعايتك الصحية للمخاطر الفردية، قد يُنصح بفصل كلا اللقاحين بمدة تبلغ ٤ أسابيع على سبيل المثال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للبالغين، يمكن إعطاء بريفينار ٢٠ في نفس الوقت مع لقاح الحمض النووي الريبوزي المرسال المضاد لكوفيد-١٩.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الطبيب أو الصيدلي أو الممرضة، إذا كنت أنت أو طفلك تتناولان أو تناولتما مؤخرًا أو قد تتناولان أي أدوية أخرى أو إذا تلقيتما مؤخرًا أي لقاحات أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تلقي هذا اللقاح.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير بريفينار ٢٠ على القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p dir="RTL">لا يوجد تأثير لبريفينار ٢٠ أو له تأثير لا يذكر على القدرة على القيادة واستخدام الآلات. مع ذلك، فقد تؤثر بعض الأعراض المذكورة تحت القسم ٤ &quot;الأعراض الجانبية&quot; بشكل مؤقت على القدرة على القيادة أو استخدام الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات بريفينار ٢٠</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي بريفينار ٢٠ على الصوديوم</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة؛ أي أنه يُعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;يقوم الطبيب أو الممرضة بحقن الجرعة الموصى بها (٠,٥ مل) من اللقاح في الجزء العلوي من ذراعك أو في عضلة فخذ طفلك أو الجزء العلوي من ذراعه.</p><p>&nbsp;</p><p dir="RTL"><u>الرضّع من عمر ٦ أسابيع إلى </u><u>۱</u><u>٥ شهرًا</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يتلقى طفلك مجموعة تلقيح أولية مكونة من ثلاث جرعات حقن من اللقاح تليها جرعة معززة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن إعطاء جرعة الحقن الأولى ابتداءً من عمر ٦ أسابيع إلى ۸ أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم إعطاء كل جرعة حقن في مرة منفصلة مع فاصل زمني لا يقل عن ٤ أسابيع بين الجرعات باستثناء جرعة الحقن الأخيرة (الجرعة المعززة)، التي سيتم إعطاؤها بين ۱۱ و۱٥ شهرًا من العمر.</p><p dir="RTL">سيتم إبلاغك بالموعد الذي يتعين عليك العودة فيه ليتلقى طفلك جرعة الحقن التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على التوصيات الرسمية في دولتك، يرجى التحدث إلى طبيبك أو الصيدلي أو الممرضة للحصول على المزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال المبتسرون (المولودون قبل الأسبوع رقم </u><u>۳</u><u>٧ من الحمل)</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">سيتلقى طفلك مجموعة تلقيح أولية مكونة من ثلاث جرعات حقن تليها جرعة معززة. يمكن إعطاء جرعة الحقن الأولى ابتداءً من عمر ٦ أسابيع بحيث يفصل بين الجرعات ما لا يقل عن ٤ أسابيع. ثم بين عمر ۱۱ و۱٥ شهرًا، سيتلقى طفلك جرعة حقن رابعة (جرعة معززة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرُّضع الذين لم يتلقوا اللقاح من عمر ٧ أشهر إلى أقل من </u><u>۱۲</u><u> شهرًا</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">ينبغي أن يتلقى الرُّضع الذين تتراوح أعمارهم بين <strong>٧ أشهر إلى أقل من </strong><strong>۱۲</strong><strong> شهرًا</strong> ثلاث جرعات حقن. يتم إعطاء أول جرعتين بحيث يفصل بينهما ما لا يقل عن ٤ أسابيع. ثم سيتم إعطاء جرعة الحقن الثالثة في العام الثاني من العمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال الذين لم يتلقوا اللقاح من عمر </u><u>۱۲</u><u> شهرًا إلى أقل من </u><u>۲</u><u>٤ شهرًا</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">ينبغي أن يتلقى الأطفال الذين تتراوح أعمارهم بين <strong>۱۲</strong><strong> شهرًا إلى أقل من </strong><strong>۲</strong><strong>٤ شهرًا</strong> جرعتي حقن، بحيث يفصل بينهما ما لا يقل عن ۸ أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال الذين لم يتلقوا اللقاح من عمر عامين إلى أقل من ٥ أعوام</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يتلقى الأطفال الذين تتراوح أعمارهم بين <strong>عامين إلى أقل من ٥ أعوام</strong> جرعة حقن واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال من عمر </u><u>۱</u><u>٥ شهرًا إلى أقل من ٥ أعوام الذين سبق أن تلقوا اللقاح بالكامل باستخدام بريفينار </u><u>۱۳</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">سيتلقى الأطفال الذين تتراوح أعمارهم بين <strong>۱</strong><strong>٥ شهرًا إلى أقل من ٥ أعوام</strong> وسبق أن تلقوا اللقاح بالكامل باستخدام بريفينار ۱۳ جرعة حقن واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون من عمر ٥ أعوام إلى أقل من </u><u>۱۸</u><u> عامًا بغض النظر عن تاريخ التلقيح السابق باستخدام بريفينار </u><u>۱۳</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتلقى الأطفال والمراهقون الذين تتراوح أعمارهم بين <strong>٥ أعوام إلى أقل من </strong><strong>۱۸</strong><strong> عامًا</strong> جرعة حقن واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا سبق أن تلقى طفلك بريفينار ۱۳، فينبغي أن تمر فترة زمنية لا تقل عن ۸ أسابيع قبل تلقي بريفينار ٢٠.</p><p>&nbsp;</p><p dir="RTL"><u>البالغون</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">ينبغي أن يتلقى البالغون جرعة حقن واحدة.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا ما سبق أن تلقيت لقاح المكورات الرئوية من قبل.</p><p><u>&nbsp;</u></p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام بريفينار ٢٠، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الفئات الخاصة من المرضى</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">يُمكن للأفراد الأكثر عرضة لخطر الإصابة بعدوى المكورات الرئوية (مثل المصابين بمرض الخلايا المنجلية أو بعدوى فيروس نقص المناعة البشرية (HIV))، بما في ذلك أولئك الذين سبق لهم تلقي لقاح المكورات الرئوية عديد السكاريد جامع ل ٢۳، أن يتلقوا جرعة واحدة على الأقل من بريفينار ٢٠.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكن للأفراد الذين خضعوا لعملية زرع خلايا جذعية مكونة للدم أن يتلقوا ثلاث جرعات حقن، حيث يتم إعطاء جرعة الحقن الأولى بعد ۳ إلى ٦ أشهر من عملية الزرع مع فاصل زمني لا يقل عن ٤ أسابيع بين الجرعات. يوصى بتلقي جرعة حقن رابعة (جرعة معززة) بعد ٦ أشهر من جرعة الحقن الثالثة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع اللقاحات، يمكن أن يسبب بريفينار ٢٠ أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة لبريفينار ٢٠</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت علامات تشير إلى الإصابة بالأعراض الجانبية الخطيرة التالية (انظر أيضًا القسم ٢):</p><p dir="RTL">&nbsp;تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق (التورم)، ضيق التنفس، الأزيز (التشنج القصبي) &ndash; قد تكون هذه علامات على الإصابة بتفاعل حساسية شديد مثل التأق، بما في ذلك الصدمة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الأعراض الجانبية التالية تلك التي تم الإبلاغ عن حدوثها عند إعطاء بريفينار ٢٠ للرُّضع والأطفال (من عمر ٦ أسابيع إلى أقل من ٥ أعوام):</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong>: قد تحدث مع ما يزيد عن جرعة واحدة من بين كل ١٠ جرعات من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن لجميع الأطفال: الاحمرار، أو التيبس، أو التورم، الألم أو الإيلام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن بعد تلقي الجرعة المعززة وفي الأطفال من عمر عامين إلى أقل من ٥ أعوام: الاحمرار، أو التيبس، أو التورم الأكبر من ۲,۰ إلى ٧٫٠ سم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong>: قد تحدث مع ما يصل إلى جرعة واحدة من بين كل ١٠ جرعات من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع في درجة الحرارة يبلغ ۳۸,۹ درجة مئوية أو أكثر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن بعد مجموعة التلقيح الأولية: الاحمرار، أو التيبس، أو التورم الأكبر من ۲,۰ إلى ٧,۰ سم، الألم أو الإيلام بدرجة تؤثر على الحركة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong>: قد تحدث مع ما يصل إلى جرعة واحدة من بين كل ١٠٠ جرعة من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات، بما في ذلك الناتجة عن ارتفاع درجة الحرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الأرتيكاريا أو الطفح الجلدي الشبيه بالأرتيكاريا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن: الاحمرار، أو التيبس، أو التورم الأكبر من ٧,۰ سم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong>: قد تحدث مع ما يصل إلى جرعة واحدة من بين كل ۱۰۰۰ جرعة من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (فرط التحسس) في موضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظ ظهور الأعراض الجانبية التالية مع تلقي بريفينار ١٣، ويمكن أيضًا أن تظهر مع بريفينار ٢٠</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء أو الإصابة بحالة تشبه الصدمة (نوبة من نقص الاستجابة ونقص التوتر العضلي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية (فرط التحسس)، بما في ذلك تورم الوجه و/أو الشفتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البكاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوم المضطرب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي تم الإبلاغ عن حدوثها عند إعطاء بريفينار ٢٠ للأطفال والمراهقين (من عمر ٥ أعوام إلى أقل من </strong><strong>۱۸ </strong><strong>عامًا):</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong>:<strong> </strong>قد تحدث مع ما يزيد عن جرعة واحدة من بين كل ١٠ جرعات من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن: ألم أو إيلام أو احمرار أو تيبس أو تورم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong>: قد تحدث مع ما يصل إلى جرعة واحدة من بين كل ١٠ جرعات من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن: ألم أو إيلام يؤثران على الحركة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong>: قد تحدث مع ما يصل إلى جرعة واحدة من بين كل ١٠٠ جرعة من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الأرتيكاريا أو الطفح الجلدي الشبيه بالأرتيكاريا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظ ظهور الأعراض الجانبية التالية مع تلقي بريفينار ١٣، ويمكن أيضًا أن تظهر مع بريفينار ٢٠:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوم المضطرب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">كانت هناك أعراض جانبية مماثلة لدى الأطفال والمراهقين المصابين بعدوى فيروس نقص المناعة البشرية أو مرض الخلايا المنجلية أو الذين خضعوا بزراعة الخلايا الجذعية المكونة للدم، ومع ذلك، كان معدل تكرار الأعراض مثل القيء والإسهال والحمى وآلام المفاصل والأعراض في موقع الحقن: الألم أو الإيلام اللذان يؤثران على الحركة، شائعة جدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظ ظهور الأعراض الجانبية التالية مع تلقي بريفينار ١٣ في تجربة ما بعد التسويق لدى الأطفال، ويمكن أيضًا أن تظهر مع بريفينار ٢٠:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد، بما في ذلك الصدمة (الوهط القلبي الوعائي)؛ تورم الشفتين أو الوجه أو الحلق (الوذمة الوعائية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد أو الغدد الليمفاوية (تضخم الغدد اللمفية) القريبة من موضع حقن اللقاح، كتلك الموجودة تحت الذراع أو في الأربية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع الحقن: الشرى (الأرتيكاريا)، والاحمرار والتهيج (التهاب الجلد) والحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يسبب ظهور بقع حمراء مثيرة للحكة (الحمامى متعددة الأشكال).</p><p dir="RTL">&nbsp;</p><p><strong>تتضمن الأعراض الجانبية التالية تلك </strong><strong>التي تم الإبلاغ عن حدوثها </strong><strong>عند إعطاء بريفينار ٢٠ للبالغين:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong>: قد تحدث هذه الأعراض مع ما يزيد عن جرعة واحدة من بين كل ١٠ جرعات من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل وآلام العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم/إيلام في موضع الحقن والتعب.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong>: قد تحدث هذه الأعراض مع ما يصل إلى جرعة واحدة من بين كل ١٠ جرعات من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم في موضع الحقن، والاحمرار في موضع الحقن، والحمى.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>غير شائعة</strong>: قد تحدث هذه الأعراض مع ما يصل إلى جرعة واحدة من بين كل ١٠٠ جرعة من اللقاح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، والغثيان، والقيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي وتورُّم الوجه أو الشفتين أو الفم أو اللسان أو الحلق وهو ما قد يسبب صعوبة في البلع أو التنفس (الوذمة الوعائية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في موضع الحقن، وتورم الغدد في الرقبة أو الإبط أو الأربية (تضخم العقد اللمفية)، والشرى في موضع الحقن (الأرتيكاريا)، والقشعريرة.</p><p>&nbsp;</p><p dir="RTL"><strong>لوحظ ظهور الأعراض الجانبية التالية مع تلقي بريفينار ١٣ ويمكن أيضًا ظهورها مع بريفينار ٢٠:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يسبب وجود بقع حمراء مثيرة للحكة (بقع حمراء عديدة الأشكال).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تهيج موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقييد حركة الذراع.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:348px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">&nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;ا</p><p dir="RTL">&nbsp;احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية والملصق بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يُحفظ في البراد (الثلاجة) (من درجتين مئويتين إلى ٨ درجات مئوية).</p><p>&nbsp;</p><p dir="RTL">ينبغي استخدام بريفينار ٢٠ في أسرع وقت ممكن بعد إزالته من التبريد.</p><p>&nbsp;</p><p dir="RTL">&nbsp;لا تقم بتجميده. تخلص من اللقاح إذا تم تجميده.</p><p>&nbsp;</p><p dir="RTL">&nbsp;تشير بيانات الاستقرار إلى أن اللقاح يكون مستقرًا لمدة ٩٦ ساعة عند تخزينه في درجات حرارة تتراوح من ٨ درجات مئوية إلى ٢٥ درجة مئوية، أو ٧٢ ساعة عند تخزينه في درجات حرارة تتراوح من ٠ درجة مئوية إلى درجتين مئويتين. في نهاية هذه الفترات الزمنية، ينبغي استخدام بريفينار ٢٠ أو التخلص منه. هذه البيانات موجهة لإرشاد أخصائيي الرعاية الصحية في حالة اختلال درجة الحرارة المؤقت فقط.</p><p>&nbsp;</p><p dir="RTL">ينبغي أن تُخزن المحاقن مسبقة التعبئة في البراد (الثلاجة) بشكل أفقي للتقليل من وقت إعادة التوزيع.</p><p>&nbsp;</p><p dir="RTL">&nbsp;لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي مقترنات عديد السكاريد مع CRM<sub>197</sub> التي تتكون من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٢.٢ ميكروجرام من عديد سكاريد الأنماط المصلية ١ و٣ و٤ و٥ و٦A و٧F و٨ و٩V و١٠A و١١A و١٢F و١٤ و١٥B و١٨C و١٩A و١٩F و٢٢F و٢٣F و٣٣F</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٤.٤ ميكروجرام من عديد سكاريد النمط المصلي ٦B</p><p>&nbsp;</p><p dir="RTL">تحتوي الجرعة الواحدة (٠.٥ مل) على حوالي ٥١ ميكروجرام من البروتين الحامل CRM<sub>197</sub>، ممتز على فوسفات الألومنيوم (٠.١٢٥ ملجم ألومنيوم).</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي كلوريد الصوديوم وحمض السكسينيك وبولي سوربات ٨٠ وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يأتي اللقاح في صورة معلق أبيض اللون مخصص للحقن، معبأ في محقنة مسبقة التعبئة مُخصصة لإعطاء جرعة واحدة (٠,٥ مل). يتوفر في عبوات بأحجام تحتوي على محقنة واحدة و١٠ محاقن و٥۰ محقنة، مزودة بإبر أو بدونها.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">فايزر يوروب إم أي إي إي جي، بلجيكا</p><p dir="RTL">&nbsp;</p><p><strong>&rlm;الشركة الصانعة</strong></p><p>فايزر إيرلاند فارماسوتيكلز</p><p>دبلن، ايرلندا</p><p>&nbsp;</p><p><strong>شركة التغليف والفسح النهائي</strong></p><p>فايزر مانفاكشرينج بيلجيم إن في</p><p dir="RTL">بورس، بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prevenar 20 suspension for injection in pre-filled syringe
Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One dose (0.5 mL) contains:

Pneumococcal polysaccharide serotype 11,2	2.2 µg
Pneumococcal polysaccharide serotype 31,2	2.2 µg
Pneumococcal polysaccharide serotype 41,2	2.2 µg
Pneumococcal polysaccharide serotype 51,2	2.2 µg
Pneumococcal polysaccharide serotype 6A1,2	2.2 µg
Pneumococcal polysaccharide serotype 6B1,2	4.4 µg
Pneumococcal polysaccharide serotype 7F1,2	2.2 µg
Pneumococcal polysaccharide serotype 81,2	2.2 µg
Pneumococcal polysaccharide serotype 9V1,2	2.2 µg 
Pneumococcal polysaccharide serotype 10A1,2	2.2 µg
Pneumococcal polysaccharide serotype 11A1,2	2.2 µg
Pneumococcal polysaccharide serotype 12F1,2	2.2 µg
Pneumococcal polysaccharide serotype 141,2	2.2 µg 
Pneumococcal polysaccharide serotype 15B1,2	2.2 µg
Pneumococcal polysaccharide serotype 18C1,2	2.2 µg
Pneumococcal polysaccharide serotype 19A1,2	2.2 µg
Pneumococcal polysaccharide serotype 19F1,2	2.2 µg
Pneumococcal polysaccharide serotype 22F1,2	2.2 µg
Pneumococcal polysaccharide serotype 23F1,2	2.2 µg
Pneumococcal polysaccharide serotype 33F1,2	2.2 µg

1Conjugated to CRM197 carrier protein (approximately 51 µg per dose)
2Adsorbed on aluminium phosphate (0.125 mg aluminium per dose)

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection.
The vaccine is a homogeneous white suspension.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Active immunisation for the prevention of invasive disease, pneumonia, and acute otitis media caused by <em>Streptococcus pneumoniae</em> in infants, children, and adolescents from 6&nbsp;weeks to less than 18&nbsp;years of age.&nbsp;</p><p>&nbsp;</p><p>Active immunisation for the prevention of invasive disease and pneumonia caused by<em> Streptococcus pneumoniae </em>in individuals 18&nbsp;years of age and older.</p><p>&nbsp;</p><p>See sections&nbsp;4.4&nbsp;and&nbsp;5.1 for information on protection against specific pneumococcal serotypes.</p><p>&nbsp;</p><p>Prevenar&nbsp;20 should be used in accordance with official recommendations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>&nbsp;</p><p>It is recommended that infants who receive a first dose of Prevenar&nbsp;20 complete the vaccination course with Prevenar&nbsp;20.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Vaccination schedule in infants and children 6&nbsp;weeks to 15&nbsp;months of age</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>4-dose series (three-dose primary series followed by a booster dose)</em></p></td><td style="vertical-align:top"><p>The primary infant series consists of three doses, each of 0.5mL, with the first dose usually given at 2&nbsp;months of age and with an interval of at least 4&nbsp;weeks between doses. The first dose may be given as early as 6&nbsp;weeks of age. The fourth (booster) dose is recommended between 11 and 15&nbsp;months of age (see section 5.1).</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vaccination schedule for individuals 18&nbsp;years of age and older</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Individuals 18&nbsp;years of age and older</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prevenar&nbsp;20 is to be administered as a single dose to individuals 18&nbsp;years of age and older.</p><p>&nbsp;</p><p>The need for revaccination with a subsequent dose of Prevenar&nbsp;20 has not been established.</p><p>&nbsp;</p><p>No data on sequential vaccination with other pneumococcal vaccines or a booster dose are available for Prevenar&nbsp;20. Based on the clinical experience with Prevenar&nbsp;13 (a pneumococcal conjugate vaccine consisting of 13 polysaccharide conjugates that are also in Prevenar&nbsp;20), if the use of 23-valent pneumococcal polysaccharide vaccine (Pneumovax&nbsp;23 [PPSV23]) is considered appropriate, Prevenar&nbsp;20 should be given first (see section&nbsp;5.1).</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>No or only limited data are available for Prevenar&nbsp;20 in infants below 6 weeks, preterm, older unvaccinated, or partially vaccinated infants and children (see sections 4.4, 4.8 and 5.1). The following dosing recommendations are predominantly based on experience with Prevenar 13.</p><p>&nbsp;</p><p><em>Infants below 6 weeks of age</em></p><p>&nbsp;</p><p>The safety and efficacy of Prevenar&nbsp;20 in infants below 6&nbsp;weeks have not been established. No data are available.</p><p><em>&nbsp;</em></p><p><em>Preterm infants (less than 37&nbsp;weeks of gestation)</em></p><p><em><sup>&nbsp;</sup></em></p><p>The recommended immunisation series for Prevenar&nbsp;20 consists of four&nbsp;doses, each of 0.5&nbsp;mL. The primary infant series consists of three doses, with the first dose given at 2&nbsp;months of age and with an interval of at least 4&nbsp;weeks between doses. The first dose may be given as early as 6&nbsp;weeks of age. The fourth (booster) dose is recommended between 11&nbsp;and 15&nbsp;months of age (see sections 4.4 and 5.1).</p><p><em>&nbsp;</em></p><p>Unvaccinated infants 7&nbsp;months to less than 12&nbsp;months of age</p><p>&nbsp;</p><p>Two doses, each of 0.5&nbsp;mL, with an interval of at least 4&nbsp;weeks between doses. A third dose is recommended in the second year of life.<strong> </strong></p><p><strong>&nbsp;</strong></p><p>Unvaccinated children 12&nbsp;months to less than 24&nbsp;months of age</p><p>&nbsp;</p><p>Two doses, each of 0.5&nbsp;mL, with an interval of at least 8&nbsp;weeks between doses.</p><p>&nbsp;</p><p>Unvaccinated children 2&nbsp;years to less than 5&nbsp;years of age</p><p>&nbsp;</p><p>One single dose of 0.5&nbsp;mL.</p><p><strong><em>&nbsp;</em></strong></p><p>Children 15&nbsp;months to less than 5&nbsp;years of age previously fully vaccinated with Prevenar 13</p><p>&nbsp;</p><p>One single dose (0.5&nbsp;mL) given on an individual basis according to official recommendations to elicit immune responses to the additional serotypes.</p><p>&nbsp;</p><p>If Prevenar 13 was administered, at least 8&nbsp;weeks should elapse before administering Prevenar&nbsp;20 (see section 5.1).</p><p><em>&nbsp;</em></p><p>Children and adolescents 5&nbsp;years to less than 18&nbsp;years of age regardless of prior Prevenar 13 vaccination</p><p>&nbsp;</p><p>One single dose (0.5&nbsp;mL) given on an individual basis according to official recommendations.</p><p>&nbsp;</p><p>If Prevenar 13 was administered, at least 8&nbsp;weeks should elapse before administering Prevenar&nbsp;20 (see section 5.1).</p><p>&nbsp;</p><p><em>Special populations</em></p><p>&nbsp;</p><p>There are no data with Prevenar&nbsp;20 in special populations.</p><p>&nbsp;</p><p>Experience from clinical studies with Prevenar&nbsp;13 (a pneumococcal conjugate vaccine consisting of 13&nbsp;polysaccharide conjugates that are also in Prevenar&nbsp;20) are available in children and adults at higher risk of pneumococcal infection including immunocompromised children and adults with human immunodeficiency virus (HIV) infection or haematopoietic stem cell transplant (HSCT), and children with sickle cell disease (SCD) (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p>Based on these data, the following posology was recommended for Prevenar 13:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Individuals at higher risk of pneumococcal infection (e.g., individuals with SCD or HIV infection), including those previously vaccinated with 1 or more doses of PPSV23, were recommended to receive at least 1&nbsp;dose of Prevenar&nbsp;13.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In individuals with a HSCT, the recommended immunisation series with Prevenar&nbsp;13 consisted of 4&nbsp;doses of 0.5&nbsp;mL each. The primary series consisted of 3&nbsp;doses, with the first dose given 3 to 6&nbsp;months after HSCT and with an interval of at least 4 weeks between doses. A booster dose was recommended 6&nbsp;months after the third dose (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p>The recommended dosing of Prevenar&nbsp;13 may be considered in guiding vaccination with Prevenar&nbsp;20 in high-risk populations. For information on responses to pneumococcal vaccines in immunocompromised individuals, please also refer to sections 4.4. and 5.1.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For intramuscular use only.</p><p>&nbsp;</p><p>The vaccine (0.5&nbsp;mL) should be given by intramuscular injection. The preferred sites are the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults. Prevenar&nbsp;20 should be administered, with care to avoid injection into or near nerves and blood vessels.</p><p>&nbsp;</p><p>For instructions on the handling of the vaccine before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients listed in section 6.1, or to diphtheria toxoid.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not inject Prevenar 20 intravascularly.</p><p>&nbsp;</p><p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.</p><p>&nbsp;</p><p><u>Concurrent illness</u></p><p>&nbsp;</p><p>Vaccination should be postponed in individuals suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.</p><p><u>&nbsp;</u></p><p><u>Thrombocytopenia and coagulation disorders</u></p><p>&nbsp;</p><p>The vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.</p><p>&nbsp;</p><p>The risk of bleeding in patients with coagulation disorders needs to be carefully evaluated before intramuscular administration of any vaccine, and subcutaneous administration should be considered if the potential benefit clearly outweighs the risks.</p><p>&nbsp;</p><p><u>Protection against pneumococcal disease</u></p><p>&nbsp;</p><p>Prevenar&nbsp;20 may only protect against <em>Streptococcus pneumoniae</em> serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia or otitis media (OM). As with any vaccine, Prevenar&nbsp;20 may not protect all individuals receiving the vaccine from invasive pneumococcal disease (IPD), pneumonia or OM. For the most recent epidemiological information in your country, you should consult with the relevant national organisation.</p><p>&nbsp;</p><p><u>Immunocompromised individuals</u></p><p>&nbsp;</p><p>Safety and immunogenicity data on Prevenar&nbsp;20 are not available for individuals in immunocompromised groups. Vaccination should be considered on an individual basis.</p><p>&nbsp;</p><p>Based on experience with pneumococcal vaccines, some individuals with altered immunocompetence may have reduced immune responses to Prevenar&nbsp;20.</p><p>&nbsp;</p><p>Individuals with impaired immune response, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunisation. The clinical relevance of this is unknown.</p><p>&nbsp;</p><p>Safety and immunogenicity data with Prevenar 13 (a pneumococcal conjugate vaccine consisting of 13&nbsp;polysaccharide conjugates that are also in Prevenar&nbsp;20) are available for individuals with HIV infection, SCD or with a HSCT (see sections&nbsp;4.8 and&nbsp;5.1). Prevenar&nbsp;20 should be used in accordance with official recommendations.</p><p>&nbsp;</p><p>In adults across all studied age groups, formal non-inferiority criteria were met although numerically lower geometric mean titres (GMTs) were observed with Prevenar&nbsp;20 for most of the serotypes compared to Prevenar 13 (see section 5.1), In children, numerically lower immunoglobulin G (IgG) geometric mean concentrations (GMCs) were observed for all shared serotypes compared with Prevenar&nbsp;13 (see section 5.1). The clinical relevance of these observations for immunocompromised individuals are unknown.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The potential risk of apnoea and the need for respiratory monitoring for 48 to 72&nbsp;h should be considered when administering the primary immunisation series to very premature infants (born less than or equal to 28&nbsp;weeks of gestation), and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.</p><p>&nbsp;</p><p><u>Excipient</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Different injectable vaccines should always be administered at different vaccination sites.</p><p>&nbsp;</p><p>Do not mix Prevenar&nbsp;20 with other vaccines or medicinal products in the same syringe.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>In infants and children, 6&nbsp;weeks to less than 5 years of age, Prevenar&nbsp;20 can be administered concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular pertussis, hepatitis B, <em>Haemophilus influenzae</em> type b, inactivated poliomyelitis, measles, mumps, rubella, and varicella vaccines. In clinical trials, rotavirus vaccines were permitted to be administered concomitantly with Prevenar&nbsp;20 and no safety concerns were observed.</p><p>&nbsp;</p><p><u>Individuals 18&nbsp;years of age and older</u></p><p>&nbsp;</p><p>Prevenar&nbsp;20 may be administered concomitantly with seasonal influenza vaccine (QIV; surface antigen, inactivated, adjuvanted). In subjects with underlying conditions associated with a high risk of developing life-threatening pneumococcal disease, consideration may be given to separating administrations of QIV and Prevenar&nbsp;20 (e.g., by approximately 4 weeks). In a double-blind, randomised study (B7471004) in adults 65 years of age and older, the immune response was formally non-inferior, however numerically lower titres were observed for all pneumococcal serotypes included in Prevenar&nbsp;20 when given concomitantly with seasonal influenza vaccine (QIV, surface antigen, inactivated, adjuvanted) compared to when Prevenar&nbsp;20 was given alone. The clinical relevance of this finding is unknown.</p><p>&nbsp;</p><p>Prevenar&nbsp;20 can be administered concomitantly with COVID-19 mRNA vaccine (nucleoside modified).</p><p>&nbsp;</p><p>There are no data on the concomitant administration of Prevenar&nbsp;20 with other vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>&nbsp;</p><p>There are no data on the use of Prevenar&nbsp;20 in pregnant women.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.</p><p>&nbsp;</p><p>Administration of Prevenar&nbsp;20 in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.</p><p>&nbsp;</p><p>Breast-feeding</p><p>&nbsp;</p><p>It is unknown whether Prevenar&nbsp;20 is excreted in human milk.</p><p>&nbsp;</p><p>Fertility</p><p>&nbsp;</p><p>No human data on the effect of Prevenar&nbsp;20 on fertility are available. Animal studies do not indicate direct or indirect harmful effects with respect to female fertility (see section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevenar 20 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section&nbsp;4.8 may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The safety of Prevenar&nbsp;20 was evaluated in 5,987 participants, 6&nbsp;weeks of age to less than 18&nbsp;years of age, in five clinical trials (one Phase 2 and four Phase 3), four randomised, double-blind, active‑controlled clinical trials and one single-arm clinical trial; 3,664 participants received at least 1 dose of Prevenar&nbsp;20, and 2,323&nbsp;participants received Prevenar&nbsp;13 (control vaccine).</p><p><u>&nbsp;</u></p><p><em><u>Participants</u></em><u> 6&nbsp;weeks to less than 15&nbsp;months of age </u></p><p><u>&nbsp;</u></p><p>Clinical trials were conducted in healthy infants 6&nbsp;weeks to less than 15&nbsp;months of age using a 3-dose schedule or a 4-dose schedule (see section 5.1). In these infant trials, 5,156 participants received at least 1 dose of vaccine: 2,833 received Prevenar&nbsp;20, and 2,323&nbsp;received Prevenar&nbsp;13. Overall, approximately 90% of participants in each group received all doses through the study-specified toddler dose. In all studies, local reactions and systemic events were collected after each dose, and adverse events (AEs) were collected in all studies from the first dose through 1&nbsp;month after the last infant vaccination and from the toddler dose through 1 month after the toddler dose. Serious adverse events were evaluated through 1&nbsp;month after the last dose in the Phase 3 trial B7471012 (Study 1012) and through 6&nbsp;months after the last dose in Phase 3 trials (Studies 1011, 1013) and Phase 2 trial (Study&nbsp;1003).</p><p>&nbsp;</p><p>Prevenar&nbsp;20 was well tolerated, when administered in a 3-dose and a 4-dose series, in the infant study populations with low rates of severe local reactions and systemic events, and most reactions resolving within 1 to 3&nbsp;days. The percentages of participants with local reactions and systemic events after Prevenar&nbsp;20 were generally similar to those after Prevenar&nbsp;13. The most frequently reported local reactions and systemic events after any dose of Prevenar&nbsp;20 were irritability, drowsiness, and pain at injection site. In these studies, Prevenar&nbsp;20 was co-administered or permitted to be administered with certain routine paediatric vaccines (see section 4.5).</p><p><u>&nbsp;</u></p><p>Study 1012 was a pivotal, double-blind, randomised, active-controlled Phase 3 trial, in which 601&nbsp;healthy infants received Prevenar&nbsp;20 in a 3-dose series. The most frequently reported (&gt;&nbsp;10%) adverse reactions after any dose of Prevenar&nbsp;20 were irritability (71.0% to 71.9%), drowsiness/increased sleep (50.9% to 61.2%), pain at injection site (22.8% to 42.4%), decreased appetite (24.7% to 39.3%), redness at the injection site (25.3% to 36.9%), swelling at the injection site (21.4% to 29.8%), and fever &ge;&nbsp;38.0&nbsp;℃ (8.9% to 24.3%). Most adverse reactions occurred within 1 to 2 days following vaccination and were mild or moderate in severity and of short duration (1 to 2 days).</p><p>&nbsp;</p><p>Studies 1011, 1013 and 1003, were double-blind, randomised, active-controlled trials that included 2,232 healthy infants, vaccinated with Prevenar&nbsp;20 in a 4-dose series. The most frequently reported (&gt;&nbsp;10%) adverse reactions observed after any dose of Prevenar&nbsp;20 in infants were irritability (58.5% to 70.6%), drowsiness/increased sleep (37.7% to 66.2%), pain at injection site (32.8% to 45.5%), decreased appetite (23.0% to 26.4%), redness at the injection site (22.6% to 24.5%), and swelling at the injection site (15.1% to 17.6%). Most adverse reactions were mild or moderate following vaccination and most reactions resolving within 1 to 3&nbsp;days. Severe reactions were reported infrequently.</p><p>&nbsp;</p><p>In Study 1013, the local reactions and systemic events in the preterm subgroup (111 infants born at 34&nbsp;to less than 37&nbsp;weeks of gestation) were similar to or lower than the term infants in the study. In the preterm subgroup, the frequency of any reported local reaction was 31.7% to 55.3% in the Prevenar&nbsp;20 group, and any systemic event was 65.0% to 85.5% in the Prevenar&nbsp;20 group.</p><p>&nbsp;</p><p><em><u>Participants&nbsp;</u></em><u>aged 15&nbsp;months to </u><em><u>less than 18&nbsp;years of age </u></em></p><p>&nbsp;</p><p>In the Phase 3 trial B7471014 (Study 1014), 831 participants 15&nbsp;months to less than 18&nbsp;years of age received a single dose of Prevenar&nbsp;20 in four age groups (209&nbsp;participants 15 to less than 24&nbsp;months of age; 216&nbsp;participants 2&nbsp;years&nbsp;to less than 5&nbsp;years of age; 201&nbsp;participants 5&nbsp;years to less than 10&nbsp;years age; and 205&nbsp;participants 10 years to less than 18&nbsp;years of age). The participants less than 5&nbsp;years of age had received at least 3 prior doses of Prevenar 13.</p><p>&nbsp;</p><p>The most frequently reported (&gt;&nbsp;10%) adverse reactions observed after any dose of Prevenar&nbsp;20 in participants less than 2&nbsp;years of age were irritability (61.8%), pain at the injection site (52.5%), drowsiness/increased sleep (41.7%), redness at the injection site (37.7%), decreased appetite (25.0%), swelling at the injection site (22.1%), and fever &ge;&nbsp;38.0&nbsp;&deg;C&nbsp;(11.8%). In participants aged 2 years and older, the most frequently reported adverse reactions were pain at the injection site (66.0% to 82.9%), muscle pain (26.5% to 48.3%), redness at the injection site (15.1% to 39.1%), fatigue (27.8% to 37.2%), headache (5.6% to 29.3%), and swelling at the injection site (15.6% to 27.1%).</p><p><u>&nbsp;</u></p><p><em>Participants&nbsp;18&nbsp;years of age and older </em></p><p>&nbsp;</p><p>The safety of Prevenar&nbsp;20 was evaluated in 4,552 participants 18&nbsp;years of age and older in six clinical trials (two Phase 1, one Phase 2, and three Phase 3), and 2,496 participants in the control groups.</p><p>&nbsp;</p><p>In the Phase 3 trials, 4,263 participants received Prevenar&nbsp;20. This, included 1,798 participants 18 through 49&nbsp;years of age, 334 participants 50 through 59&nbsp;years of age, and 2,131 participants 60&nbsp;years of age and older (1,138 were 65&nbsp;years of age and older). Of the participants who received Prevenar&nbsp;20 in the Phase 3 trials, 3,639 were na&iuml;ve to pneumococcal vaccines, 253 had previously received Pneumovax 23 (pneumococcal polysaccharide vaccine [23‑valent]; PPSV23) (&ge;&nbsp;1 to &le;&nbsp;5&nbsp;years prior to enrollment), 246 had previously received Prevenar&nbsp;13 only (&ge;&nbsp;6&nbsp;months prior to enrollment), and 125 had previously received Prevenar&nbsp;13 followed by PPSV23 (the dose of PPSV23 &ge;&nbsp;1‑year prior to enrollment).</p><p>&nbsp;</p><p>Participants in the Phase 3 trial B7471007 (Pivotal Study 1007) were evaluated for adverse events for 1&nbsp;month after vaccination, and serious adverse events through 6&nbsp;months after vaccination. This study included 447 participants 18 to 49&nbsp;years of age, 445 participants 50 to 59&nbsp;years of age, 1,985&nbsp;participants 60 to 64&nbsp;years of age, 624 participants 65 to 69&nbsp;years of age, 319 participants 70 to 79&nbsp;years of age, and 69 participants &ge;&nbsp;80&nbsp;years of age.</p><p>&nbsp;</p><p>In participants 18 to 49&nbsp;years of age in Studies 1007 and a Phase 3 trial B7471008 (Lot Consistency Study 1008), the most frequently reported adverse reactions were pain at injection site (79.2%), muscle pain (62.9%), fatigue (46.7%), headache (36.7%), and joint pain (16.2%). In participants 50 to 59 years of age in Study 1007, the most frequently reported adverse reactions were pain at injection site (72.5%), muscle pain (49.8%), fatigue (39.3%), headache (32.3%), and joint pain (15.4%). In participants &ge;&nbsp;60&nbsp;years of age in Study 1007, the most frequently reported adverse reactions were pain at injection site (55.4%), muscle pain (39.1%), fatigue (30.2%), headache (21.5%), and joint pain (12.6%). These were usually mild or moderate in intensity and resolved within a few days after vaccination.</p><p>&nbsp;</p><p>Phase&nbsp;3 Study B7471006 (Study&nbsp;1006) evaluated Prevenar&nbsp;20 in participants &ge;&nbsp;65 years of age with varying prior pneumococcal status (prior PPSV23, prior Prevenar 13 or prior Prevenar 13 followed by PPSV23). In this study, the most frequently reported adverse reactions for participants were similar in frequency to those described for participants &ge;&nbsp;60 years of age in Study 1007, with slightly higher injection site pain (61.2%) in participants with prior Prevenar 13, and joint pain (16.8%) in participants with prior Prevenar 13 followed by PPSV23.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Tabulated lists of adverse reactions from the infant Phase 2, Phase 3 clinical trials in paediatric and adult populations, and postmarketing experience are presented below.</p><p><u>&nbsp;</u></p><p><em>Adverse reactions from clinical trials </em></p><p>&nbsp;</p><p>As Prevenar&nbsp;20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the same vaccine excipients as Prevenar&nbsp;13, the adverse reactions already identified for Prevenar&nbsp;13 have been adopted for Prevenar&nbsp;20. Table&nbsp;1 presents adverse reactions reported in the Phase 2 infant trial, and the Phase&nbsp;3 trials in paediatric and adult populations, based on the highest frequency among adverse reactions, local reactions, or systemic events, after vaccination in an Prevenar&nbsp;20 group or integrated dataset. The data from clinical trials in infants reflect Prevenar&nbsp;20 administered simultaneously with other routine childhood vaccines.</p><p>&nbsp;</p><p>Adverse reactions are listed by system organ class in decreasing order of frequency and seriousness. The frequency is defined as follows: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from available data).</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 1.</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Tabulated </strong><strong>Adverse Reactions From </strong><strong>Prevenar&nbsp;20</strong><strong> Clinical Trials</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Infants/Children/Adolescents</strong></p></td><td style="vertical-align:top"><p><strong>Adults</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6 weeks to less than 5 years of age</strong></p></td><td style="vertical-align:top"><p><strong>5 years to less than 18 years of age</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity reaction including face oedema, dyspnoea, bronchospasm</p></td><td colspan="2" style="vertical-align:top"><p>Rare<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td style="vertical-align:top"><p>Very common<sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Irritability</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Crying</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Drowsiness/increased sleep</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Seizures (including febrile seizures)</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hypotonic-hyporesponsive episode</p></td><td colspan="2" style="vertical-align:top"><p>Rare<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Restless sleep/decreased sleep</p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Common<sup>a</sup></p></td><td style="vertical-align:top"><p>Uncommon<sup>b</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Common<sup>a</sup></p></td><td style="vertical-align:top"><p>Uncommon<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Common<sup>a</sup></p></td><td style="vertical-align:top"><p>Uncommon<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria or urticaria-like rash</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal</p><p>and connective</p><p>tissue Disorders</p></td><td style="vertical-align:top"><p>Muscle pain</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Joint pain</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>Fever (pyrexia)</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Fever greater than 38.9&nbsp;&deg;C</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vaccination-site erythema</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vaccination-site induration/swelling</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vaccination-site erythema or induration/swelling (&gt;&nbsp;2.0-7.0&nbsp;cm)</p></td><td colspan="2" style="vertical-align:top"><p>Very common (after toddler dose and in older children [age 2 to &lt;&nbsp;5&nbsp;years])</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common (after infant series)</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Vaccination-site erythema or induration/swelling (&gt;&nbsp;7.0&nbsp;cm)</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Vaccination-site pain/tenderness</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vaccination-site pain/tenderness causing limitation of limb movement</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common<sup>a</sup></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vaccination-site pruritus</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lymphadenopathy</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vaccination-site urticaria</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vaccination-site hypersensitivity</p></td><td colspan="2" style="vertical-align:top"><p>Rare<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp; These frequencies are based on adverse reactions (ARs) reported in clinical trials with Prevenar&nbsp;13 as these ARs were not reported in Prevenar&nbsp;20 trials of infants (Phase 2 and 3), children and adolescents less than 18 years of age, and adults 18 years and older (Phase 3); therefore, the frequency is not known.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Event reported from clinical trials in adults with Prevenar 13 with very common frequency (&ge;&nbsp;1/10).</p><p>AR not reported for Prevenar&nbsp;13, although injection-site urticaria, injection-site pruritus, and injection-site dermatitis were reported in Prevenar&nbsp;13 postmarketing experience.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em>Safety with concomitant vaccine administration in adults</em></p><p><u>&nbsp;</u></p><p>When Prevenar&nbsp;20 was administered to adults aged &ge;&nbsp;65 years together with the third (booster) dose of a COVID-19 mRNA vaccine (nucleoside modified), the tolerability profile generally resembled that of the COVID-19 mRNA vaccine (nucleoside modified) administered alone. There were a few differences in the safety profile when compared to administration of Prevenar&nbsp;20 alone. In the phase 3 trial B7471026 (Study 1026), pyrexia (13.0%) and chills (26.5%) were reported as &ldquo;very common&rdquo; with co‑administration. There was also one report of dizziness (0.5%) in the co-administration group.</p><p><u>&nbsp;</u></p><p><em>Adverse reactions from postmarketing experience</em></p><p>&nbsp;</p><p>Table&nbsp;2 includes adverse experiences that have been spontaneously reported during the postmarketing use of Prevenar&nbsp;13 in paediatric and adult populations, which may also occur with Prevenar&nbsp;20. The postmarketing safety experience with Prevenar&nbsp;13 is relevant to Prevenar&nbsp;20, as Prevenar&nbsp;20 contains all components (polysaccharide conjugates and excipients) of Prevenar&nbsp;13. These events were reported voluntarily from a population of uncertain size. Therefore, it is not possible to reliably estimate their frequency or to establish, for all events, a causal relationship to vaccine exposure.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:bottom"><p><strong>Table 2.&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions From Prevenar&nbsp;13 Postmarketing Experience</strong></p></td></tr></tbody><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Not Known</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Lymphadenopathy localised to the region of the vaccination site</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic/anaphylactoid reaction, including shock</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Angioedema, Erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Vaccination-site dermatitis, Vaccination-site urticaria, Vaccination-site pruritus</p></td></tr></tbody></table><p>Events reported spontaneously in Prevenar&nbsp;13 postmarketing experience; therefore, the frequencies could not be estimated from the available Prevenar&nbsp;20 data and are considered as not known.</p><p>&nbsp;</p><p><u>Additional information in special populations in studies with </u><u>Prevenar&nbsp;13</u></p><p>&nbsp;</p><p>Participants 6 to &lt;&nbsp;18&nbsp;years of age with HIV infection have similar frequencies of adverse reactions in Table&nbsp;1, except fever (11% to 19%), joint pain (24% to 42%), and vomiting (8% to 18%), which were very common. Participants &ge;&nbsp;18&nbsp;years of age with HIV infection have similar frequencies of adverse reactions in Table&nbsp;1, except for pyrexia (5% to 18%) and vomiting (8% to 12%) which were very common and nausea (&lt;&nbsp;1%&nbsp;to&nbsp;3%) which was common.</p><p>&nbsp;</p><p>Participants 2 to &lt;&nbsp;18&nbsp;years of age with HSCT have similar frequencies of adverse reactions in Table&nbsp;1, except vaccination-site pain causing limitation of limb movement (5% to 15%), vomiting (6% to 21%), diarrhoea (15% to 32%), and joint pain (25% to 32%), which were very common. Participants &ge;&nbsp;18&nbsp;years of age with an HSCT have similar frequencies of adverse reactions in Table&nbsp;1, except for pyrexia (4% to 15%), vomiting (6% to 21%), and diarrhoea (25% to 36%) which were very common.</p><p>&nbsp;</p><p>Participants 6 to &lt;&nbsp;18&nbsp;years of age with SCD have similar frequencies of adverse reactions in Table&nbsp;1, except vaccination-site pain causing limitation of limb movement (11% to 16%), fever (21% to 22%), vomiting (13% to 15%), diarrhoea (13% to 25%), and joint pain (40% to 45%), which were very common.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with Prevenar 20 is unlikely due to its presentation as a pre-filled syringe.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: vaccines, pneumococcal vaccines; ATC code: J07AL02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Prevenar&nbsp;20 contains 20 pneumococcal capsular polysaccharides all conjugated to CRM<sub>197</sub> carrier protein, which modifies the immune response to the polysaccharide from a T‑cell independent response to a T‑cell dependent response. The T-cell dependent response leads to an enhanced antibody response and induced functional antibodies (associated with opsonisation, phagocytosis and killing of pneumococci) to protect against pneumococcal disease, as well as the generation of memory B cells, allowing for an anamnestic (booster) response on re-exposure to the bacterium.</p><p>&nbsp;</p><p>Immune responses in children and adults, after exposure to <em>Streptococcus pneumoniae</em> or following pneumococcal vaccination, can be determined by measuring IgG or opsonophagocytic activity (OPA) responses. OPA measures functional antibody activity and is considered to be an important immunologic surrogate measure of protection against pneumococcal disease in adults. In children, multiple immunogenicity criteria are used for the clinical evaluation of pneumococcal conjugate vaccines including the proportion of vaccinated children achieving a serotype-specific IgG antibody level corresponding to &ge;&nbsp;0.35 &micro;g/mL using the WHO enzyme linked immunosorbent assay (ELISA) or an equivalent assay-specific value.</p><p>Serotype-specific immune responses that correlate with individual protection against pneumococcal disease have not been clearly defined.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p>No efficacy studies have been performed with Prevenar&nbsp;20.</p><p><strong>&nbsp;</strong></p><p><u>Immunogenicity data</u></p><p><strong>&nbsp;</strong></p><p><em>Prevenar&nbsp;20 clinical trials in infants, children and adolescents</em></p><p><u>&nbsp;</u></p><p>Immunogenicity was assessed by serotype-specific IgG response rates (the proportion of participants meeting the serotype-specific IgG level of &ge;&nbsp;0.35 &mu;g/mL or equivalent assay-specific value) and IgG GMCs at 1 month following the primary series and 1 month following the toddler dose. OPA GMTs were also measured 1 month following the primary series and following the toddler dose. The predefined concentration corresponding to 0.35 &micro;g/mL in the WHO ELISA (or equivalent assay‑specific threshold value) is only applicable at the population level and cannot be used to predict individual or serotype-specific protection against IPD. No correlate of protection exists for pneumonia and acute otitis media (AOM).</p><p>&nbsp;</p><p>Two Phase 3 clinical trials (Study 1011, Study 1012) and one Phase 2 clinical trial (Study 1003) evaluated the immunogenicity of Prevenar&nbsp;20 in a 3-dose or a 4-dose series in infants. One Phase&nbsp;3 study (Study 1014) of children 15&nbsp;months to less than 18&nbsp;years of age evaluated a single dose of Prevenar&nbsp;20.</p><p><em><u>&nbsp;</u></em></p><p><em>Immune responses following 3 and 4 doses in a 4-dose infant vaccination series</em></p><p>&nbsp;</p><p>In Study 1011, conducted in the United States and Puerto Rico, 1,991 healthy infants aged 2 months (&ge;&nbsp;42 to &le;&nbsp;98&nbsp;days) at the time of consent and born at &gt;&nbsp;36&nbsp;weeks of gestation, were randomised (1:1) and vaccinated with either Prevenar&nbsp;20 or Prevenar&nbsp;13 at approximately 2, 4, 6, and 12 to 15&nbsp;months of age. Participants also received other paediatric vaccines including a combination vaccine containing diphtheria, tetanus, pertussis (acellular), hepatitis B (rDNA), poliomyelitis (inactivated), and a <em>Haemophilus influenzae</em> type b conjugate vaccine (adsorbed) with all 3 doses, and measles, mumps, rubella combination vaccine, and varicella vaccine at the toddler dose. Rotavirus and influenza vaccines were permitted to be co-administered in the study.</p><p>&nbsp;</p><p>One month after the third infant dose, NI for the difference in percentages of participants with specified serotype-specific IgG concentrations (with a 10% NI criterion) was met for 9 of the 13 matched serotypes and missed for 4 serotypes (serotypes 3, 4, 9V, and 23F) (Table 3). Six of the 7&nbsp;additional serotypes also met the non‑inferiority criterion when compared to the lowest result for a vaccine serotype in the Prevenar 13 group (excluding serotype 3); serotype 12F missed the statistical non‑inferiority criterion. IgG GMCs 1 month after dose 3 of Prevenar&nbsp;20 were non‑inferior (with a 0.5&nbsp;NI criterion for IgG geometric mean ratio (GMR)) to those in the Prevenar&nbsp;13 group for all 13 matched serotypes. The NI criterion was also met for the 7&nbsp;additional serotypes to the lowest IgG GMC (excluding serotype&nbsp;3) among the vaccine serotypes in the Prevenar&nbsp;13 group (Table 3).</p><p>&nbsp;</p><p>The antibody levels for all 7 additional serotypes were significantly higher than the corresponding serotype in the Prevenar 13 group (Tables 3 and 4).<strong><u> </u></strong></p><p>&nbsp;</p><p>One month after the toddler dose, NI for IgG GMCs (with a 0.5 NI criterion for IgG GMR) was met for all 13&nbsp;matched serotypes. The NI criterion was also met for the 7&nbsp;additional serotypes to the lowest IgG GMC (excluding serotype&nbsp;3) among the vaccine serotypes in the Prevenar&nbsp;13 group (Table 4). Although non-inferiority was not formally tested for this endpoint, the observed differences (Prevenar&nbsp;20&nbsp;&ndash;&nbsp;Prevenar&nbsp;13) in percentages of participants with specified serotype-specific IgG concentrations 1&nbsp;month after dose 4 were greater than -10% for all 13 matched serotypes except serotype 3 (-16.4%, CI -21.0%, -11.8%). For the 7 additional serotypes, the observed differences in percentage of participants with specified serotype-specific IgG concentrations 1 month after dose 4 ranged from ‑11.5% (serotype 12F) to 1.8% (serotype 15B, 22F, and 33F) (Table 4).</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 3.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Percentage of Participants With S</strong><strong>pecified</strong><strong> Pneumococcal IgG Concentrations and Pneumococcal IgG GMCs (&micro;g/mL) One Month After Dose 3 of a 4-Dose Series, Study 1011<sup>a</sup></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Percentages of Participants With Specified IgG Concentrations<sup>b</sup></strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p><p><strong>IgG GMCs</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;20</strong></p><p><strong>N<sup>c</sup> = </strong><strong>831-833</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar 13</strong></p><p><strong>N<sup>c</sup> = 801-802</strong></p></td><td style="vertical-align:bottom"><p><strong>Difference</strong></p><p><strong>(</strong><strong>Prevenar&nbsp;20 &ndash; Prevenar 13)</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;20</strong></p><p><strong>N<sup>c</sup> = 831-833</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar 13</strong></p><p><strong>N<sup>c</sup> = 801-802</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p><p><strong>Prevenar&nbsp;20</strong></p><p><strong>/Prevenar 13</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>%</strong></p></td><td style="vertical-align:bottom"><p><strong>%</strong></p></td><td style="vertical-align:bottom"><p><strong>%</strong></p><p><strong>(95% CI<sup>d</sup>)</strong></p></td><td style="vertical-align:bottom"><p><strong>GMC<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMC<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMR</strong></p><p><strong>(95% CI<sup>e</sup>)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Serotypes</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:bottom"><p>84.9</p></td><td style="vertical-align:bottom"><p>91.1</p></td><td style="vertical-align:bottom"><p>-6.3</p><p>(-9.4, -3.1)</p></td><td style="vertical-align:bottom"><p>0.74</p></td><td style="vertical-align:bottom"><p>1.14</p></td><td style="vertical-align:bottom"><p>0.65</p><p>(0.59, 0.72)</p></td></tr><tr><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>40.5</p></td><td style="vertical-align:bottom"><p>55.2</p></td><td style="vertical-align:bottom"><p>-14.8</p><p>(-19.5, -10.0)</p></td><td style="vertical-align:bottom"><p>0.36</p></td><td style="vertical-align:bottom"><p>0.51</p></td><td style="vertical-align:bottom"><p>0.70</p><p>(0.64, 0.76)</p></td></tr><tr><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>78.2</p></td><td style="vertical-align:bottom"><p>87.5</p></td><td style="vertical-align:bottom"><p>-9.4</p><p>(-13.0, -5.8)</p></td><td style="vertical-align:bottom"><p>0.75</p></td><td style="vertical-align:bottom"><p>1.08</p></td><td style="vertical-align:bottom"><p>0.70</p><p>(0.63, 0.78)</p></td></tr><tr><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>86.2</p></td><td style="vertical-align:bottom"><p>90.5</p></td><td style="vertical-align:bottom"><p>-4.3</p><p>(-7.5, -1.2)</p></td><td style="vertical-align:bottom"><p>0.66</p></td><td style="vertical-align:bottom"><p>0.96</p></td><td style="vertical-align:bottom"><p>0.69</p><p>(0.61, 0.77)</p></td></tr><tr><td style="vertical-align:bottom"><p>6A</p></td><td style="vertical-align:bottom"><p>94.2</p></td><td style="vertical-align:bottom"><p>96.1</p></td><td style="vertical-align:bottom"><p>-1.9</p><p>(-4.0, 0.2)</p></td><td style="vertical-align:bottom"><p>1.95</p></td><td style="vertical-align:bottom"><p>2.69</p></td><td style="vertical-align:bottom"><p>0.72</p><p>(0.65, 0.81)</p></td></tr><tr><td style="vertical-align:bottom"><p>6B</p></td><td style="vertical-align:bottom"><p>88.3</p></td><td style="vertical-align:bottom"><p>92.4</p></td><td style="vertical-align:bottom"><p>-4.1</p><p>(-7.0, -1.2)</p></td><td style="vertical-align:bottom"><p>0.61</p></td><td style="vertical-align:bottom"><p>1.02</p></td><td style="vertical-align:bottom"><p>0.60</p><p>(0.51, 0.70)</p></td></tr><tr><td style="vertical-align:bottom"><p>7F</p></td><td style="vertical-align:bottom"><p>96.4</p></td><td style="vertical-align:bottom"><p>97.3</p></td><td style="vertical-align:bottom"><p>-0.9</p><p>(-2.6, 0.9)</p></td><td style="vertical-align:bottom"><p>1.71</p></td><td style="vertical-align:bottom"><p>2.29</p></td><td style="vertical-align:bottom"><p>0.75</p><p>(0.69, 0.81)</p></td></tr><tr><td style="vertical-align:bottom"><p>9V</p></td><td style="vertical-align:bottom"><p>80.3</p></td><td style="vertical-align:bottom"><p>88.8</p></td><td style="vertical-align:bottom"><p>-8.5</p><p>(-12.0, -5.0)</p></td><td style="vertical-align:bottom"><p>0.87</p></td><td style="vertical-align:bottom"><p>1.21</p></td><td style="vertical-align:bottom"><p>0.72</p><p>(0.65, 0.80)</p></td></tr><tr><td style="vertical-align:bottom"><p>14</p></td><td style="vertical-align:bottom"><p>94.2</p></td><td style="vertical-align:bottom"><p>95.4</p></td><td style="vertical-align:bottom"><p>-1.2</p><p>(-3.4, 1.0)</p></td><td style="vertical-align:bottom"><p>2.16</p></td><td style="vertical-align:bottom"><p>2.72</p></td><td style="vertical-align:bottom"><p>0.79</p><p>(0.71, 0.89)</p></td></tr><tr><td style="vertical-align:bottom"><p>18C</p></td><td style="vertical-align:bottom"><p>87.3</p></td><td style="vertical-align:bottom"><p>89.4</p></td><td style="vertical-align:bottom"><p>-2.1</p><p>(-5.3, 1.0)</p></td><td style="vertical-align:bottom"><p>1.31</p></td><td style="vertical-align:bottom"><p>1.71</p></td><td style="vertical-align:bottom"><p>0.77</p><p>(0.70, 0.84)</p></td></tr><tr><td style="vertical-align:bottom"><p>19A</p></td><td style="vertical-align:bottom"><p>96.3</p></td><td style="vertical-align:bottom"><p>98.0</p></td><td style="vertical-align:bottom"><p>-1.7</p><p>(-3.4, -0.1)</p></td><td style="vertical-align:bottom"><p>0.72</p></td><td style="vertical-align:bottom"><p>0.91</p></td><td style="vertical-align:bottom"><p>0.79</p><p>(0.72, 0.86)</p></td></tr><tr><td style="vertical-align:bottom"><p>19F</p></td><td style="vertical-align:bottom"><p>96.0</p></td><td style="vertical-align:bottom"><p>95.9</p></td><td style="vertical-align:bottom"><p>0.2</p><p>(-1.8, 2.1)</p></td><td style="vertical-align:bottom"><p>1.59</p></td><td style="vertical-align:bottom"><p>2.00</p></td><td style="vertical-align:bottom"><p>0.79</p><p>(0.73, 0.86)</p></td></tr><tr><td style="vertical-align:bottom"><p>23F</p></td><td style="vertical-align:bottom"><p>74.3</p></td><td style="vertical-align:bottom"><p>83.2</p></td><td style="vertical-align:bottom"><p>-8.9</p><p>(-12.8, -4.9)</p></td><td style="vertical-align:bottom"><p>0.82</p></td><td style="vertical-align:bottom"><p>1.25</p></td><td style="vertical-align:bottom"><p>0.66</p><p>(0.58, 0.75)</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Additional Serotypes<sup>f</sup></strong></p></td></tr><tr><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>95.8</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>12.6</p><p>(9.8, 15.6)</p></td><td style="vertical-align:bottom"><p>1.80</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>1.98</p><p>(1.81, 2.16)</p></td></tr><tr><td style="vertical-align:bottom"><p>10A</p></td><td style="vertical-align:bottom"><p>88.0</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>4.8</p><p>(1.4, 8.3)</p></td><td style="vertical-align:bottom"><p>1.21</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>1.32</p><p>(1.18, 1.49)</p></td></tr><tr><td style="vertical-align:bottom"><p>11A</p></td><td style="vertical-align:bottom"><p>90.0</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>6.9</p><p>(3.6, 10.2)</p></td><td style="vertical-align:bottom"><p>1.39</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>1.52</p><p>(1.39, 1.67)</p></td></tr><tr><td style="vertical-align:bottom"><p>12F</p></td><td style="vertical-align:bottom"><p>48.0</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>-35.1</p><p>(-39.4, -30.8)</p></td><td style="vertical-align:bottom"><p>0.55</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>0.60</p><p>(0.54, 0.67)</p></td></tr><tr><td style="vertical-align:bottom"><p>15B</p></td><td style="vertical-align:bottom"><p>97.0</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>13.8</p><p>(11.1, 16.8)</p></td><td style="vertical-align:bottom"><p>4.40</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>4.82</p><p>(4.39, 5.30)</p></td></tr><tr><td style="vertical-align:bottom"><p>22F</p></td><td style="vertical-align:bottom"><p>98.7</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>15.5</p><p>(12.9, 18.3)</p></td><td style="vertical-align:bottom"><p>3.71</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>4.06</p><p>(3.68, 4.48)</p></td></tr><tr><td style="vertical-align:bottom"><p>33F</p></td><td style="vertical-align:bottom"><p>89.3</p></td><td style="vertical-align:bottom"><p>83.2<sup>f</sup></p></td><td style="vertical-align:bottom"><p>6.1</p><p>(2.8, 9.5)</p></td><td style="vertical-align:bottom"><p>1.49</p></td><td style="vertical-align:bottom"><p>0.91<sup>g</sup></p></td><td style="vertical-align:bottom"><p>1.64</p><p>(1.46, 1.83)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: CI = confidence interval; dLIA = Luminex-based direct immunoassay; ELISA = enzyme-linked immunosorbent assay; GMC = geometric mean concentration; GMR = geometric mean ratio; IgG = immunoglobulin G; LLOQ = lower limit of quantitation.</p><p>Note: Non‑inferiority for a serotype was concluded if the lower bound of the 2-sided 95% CI for the percentage difference (Prevenar&nbsp;20 &ndash; Prevenar 13) was &gt; -10% or the lower bound of the 2-sided 95% CI for the GMR (Prevenar&nbsp;20 to Prevenar 13) was &gt;&nbsp;0.5 for that serotype.<br />Note: Assay results below the LLOQ were set to 0.5 &times; LLOQ in the analysis.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Study 1011 was conducted in the United States and the territory of Puerto Rico (NCT04382326).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Specified levels for the Prevenar&nbsp;13 serotypes are from a published bridging study (Tan CY, et al. 2018) using results from after primary infant doses, before toddler dose, and after toddler dose (schedule of 3 infant doses followed by a toddler dose) except for serotype 19A, which used results from after primary infant doses only. For the additional 7 serotypes, specified levels are from a concordance evaluation (clinical dLIA to re-test ELISA) of data from a Phase 2 Study B7471003, which also uses the schedule of 3 infant doses followed by a toddler dose.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; N = Number of participants with valid IgG concentrations.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; Two-sided CI based on the Miettinen and Nurminen method.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; GMCs, GMRs and the associated 2-sided CIs were calculated by exponentiating the means and the mean differences (PREVENAR&nbsp;20 &ndash; Prevenar 13) of the logarithm of the concentrations and the corresponding CIs (based on the Student&rsquo;s t distribution).</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the percentage differences of the 7 additional serotypes, the IgG results from serotype 23F (Prevenar&nbsp;13 serotype with the lowest percentage, excluding serotype 3) in the Prevenar 13 group was used in the comparisons for non‑inferiority. Percentages of participants with specified IgG concentrations to serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F in the Prevenar 13 group were 1.4%, 1.9%, 1.4%, 0.1%, 1.2%, 1.4% and 1.5%, respectively.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp; For the GMRs of the 7 additional serotypes, the IgG results from serotype 19A (Prevenar 13 serotype with the lowest GMC, excluding serotype 3) in the Prevenar 13 group was used in the comparisons for non‑inferiority. IgG GMCs to serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F in the Prevenar 13 group were 0.02 &micro;g/mL, 0.01 &micro;g/mL, 0.02 &micro;g/mL, 0.01 &micro;g/mL, 0.03 &micro;g/mL, 0.01 &micro;g/mL and 0.02 &micro;g/mL, respectively.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 4.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Percentage of Participants With Specified Pneumococcal IgG Concentrations and Pneumococcal IgG GMCs (&micro;g/mL) One Month After Dose 4 of a 4-Dose Series, Study&nbsp;1011<sup>a</sup></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Percentages of Participants With Specified IgG Concentrations<sup>b</sup></strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p><p><strong>IgG GMCs</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;20</strong></p><p><strong>N<sup>c</sup> = 753-755</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar 13</strong></p><p><strong>N<sup>c</sup> = 744-745</strong></p></td><td style="vertical-align:bottom"><p><strong>Difference</strong></p><p><strong>(</strong><strong>Prevenar&nbsp;20 &ndash; Prevenar 13)</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;20</strong></p><p><strong>N<sup>c</sup> = 753-755</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar 13</strong></p><p><strong>N<sup>c</sup> = 744-745</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;20</strong></p><p><strong>/Prevenar 13</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>%</strong></p></td><td style="vertical-align:bottom"><p><strong>%</strong></p></td><td style="vertical-align:bottom"><p><strong>%</strong></p><p><strong>(95% CI<sup>d</sup>)</strong></p></td><td style="vertical-align:bottom"><p><strong>GMC<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMC<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMR</strong></p><p><strong>(95% CI<sup>e</sup>)</strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Serotypes</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:bottom"><p>95.5</p></td><td style="vertical-align:bottom"><p>98.1</p></td><td style="vertical-align:bottom"><p>-2.6</p><p>(-4.5, -0.9)</p></td><td style="vertical-align:bottom"><p>1.47</p></td><td style="vertical-align:bottom"><p>2.12</p></td><td style="vertical-align:bottom"><p>0.69</p><p>(0.63, 0.76)</p></td></tr><tr><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>60.8</p></td><td style="vertical-align:bottom"><p>77.2</p></td><td style="vertical-align:bottom"><p>-16.4</p><p>(-21.0, -11.8)</p></td><td style="vertical-align:bottom"><p>0.56</p></td><td style="vertical-align:bottom"><p>0.85</p></td><td style="vertical-align:bottom"><p>0.66</p><p>(0.61, 0.73)</p></td></tr><tr><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>98.8</p></td><td style="vertical-align:bottom"><p>98.9</p></td><td style="vertical-align:bottom"><p>-0.1</p><p>(-1.3, 1.1)</p></td><td style="vertical-align:bottom"><p>3.77</p></td><td style="vertical-align:bottom"><p>4.84</p></td><td style="vertical-align:bottom"><p>0.78</p><p>(0.70, 0.86)</p></td></tr><tr><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>98.8</p></td><td style="vertical-align:bottom"><p>98.7</p></td><td style="vertical-align:bottom"><p>0.2</p><p>(-1.1, 1.4)</p></td><td style="vertical-align:bottom"><p>1.87</p></td><td style="vertical-align:bottom"><p>2.51</p></td><td style="vertical-align:bottom"><p>0.74</p><p>(0.67, 0.82)</p></td></tr><tr><td style="vertical-align:bottom"><p>6A</p></td><td style="vertical-align:bottom"><p>99.5</p></td><td style="vertical-align:bottom"><p>99.9</p></td><td style="vertical-align:bottom"><p>-0.4</p><p>(-1.2, 0.3)</p></td><td style="vertical-align:bottom"><p>9.01</p></td><td style="vertical-align:bottom"><p>11.69</p></td><td style="vertical-align:bottom"><p>0.77</p><p>(0.70, 0.85)</p></td></tr><tr><td style="vertical-align:bottom"><p>6B</p></td><td style="vertical-align:bottom"><p>99.1</p></td><td style="vertical-align:bottom"><p>99.5</p></td><td style="vertical-align:bottom"><p>-0.4</p><p>(-1.4, 0.6)</p></td><td style="vertical-align:bottom"><p>4.01</p></td><td style="vertical-align:bottom"><p>5.74</p></td><td style="vertical-align:bottom"><p>0.70</p><p>(0.62, 0.79)</p></td></tr><tr><td style="vertical-align:bottom"><p>7F</p></td><td style="vertical-align:bottom"><p>99.5</p></td><td style="vertical-align:bottom"><p>99.9</p></td><td style="vertical-align:bottom"><p>-0.4</p><p>(-1.2, 0.3)</p></td><td style="vertical-align:bottom"><p>3.91</p></td><td style="vertical-align:bottom"><p>5.18</p></td><td style="vertical-align:bottom"><p>0.76</p><p>(0.70, 0.82)</p></td></tr><tr><td style="vertical-align:bottom"><p>9V</p></td><td style="vertical-align:bottom"><p>98.3</p></td><td style="vertical-align:bottom"><p>98.9</p></td><td style="vertical-align:bottom"><p>-0.6</p><p>(-2.0, 0.6)</p></td><td style="vertical-align:bottom"><p>3.44</p></td><td style="vertical-align:bottom"><p>4.30</p></td><td style="vertical-align:bottom"><p>0.80</p><p>(0.73, 0.88)</p></td></tr><tr><td style="vertical-align:bottom"><p>14</p></td><td style="vertical-align:bottom"><p>99.2</p></td><td style="vertical-align:bottom"><p>99.6</p></td><td style="vertical-align:bottom"><p>-0.4</p><p>(-1.4, 0.5)</p></td><td style="vertical-align:bottom"><p>5.68</p></td><td style="vertical-align:bottom"><p>6.34</p></td><td style="vertical-align:bottom"><p>0.90</p><p>(0.81, 1.00)</p></td></tr><tr><td style="vertical-align:bottom"><p>18C</p></td><td style="vertical-align:bottom"><p>97.6</p></td><td style="vertical-align:bottom"><p>97.9</p></td><td style="vertical-align:bottom"><p>-0.2</p><p>(-1.8, 1.3)</p></td><td style="vertical-align:bottom"><p>3.46</p></td><td style="vertical-align:bottom"><p>4.69</p></td><td style="vertical-align:bottom"><p>0.74</p><p>(0.67, 0.82)</p></td></tr><tr><td style="vertical-align:bottom"><p>19A</p></td><td style="vertical-align:bottom"><p>99.9</p></td><td style="vertical-align:bottom"><p>99.7</p></td><td style="vertical-align:bottom"><p>0.1</p><p>(-0.5, 0.9)</p></td><td style="vertical-align:bottom"><p>3.53</p></td><td style="vertical-align:bottom"><p>4.13</p></td><td style="vertical-align:bottom"><p>0.85</p><p>(0.77, 0.94)</p></td></tr><tr><td style="vertical-align:bottom"><p>19F</p></td><td style="vertical-align:bottom"><p>98.8</p></td><td style="vertical-align:bottom"><p>98.7</p></td><td style="vertical-align:bottom"><p>0.2</p><p>(-1.1, 1.4)</p></td><td style="vertical-align:bottom"><p>5.01</p></td><td style="vertical-align:bottom"><p>5.79</p></td><td style="vertical-align:bottom"><p>0.86</p><p>(0.78, 0.96)</p></td></tr><tr><td style="vertical-align:bottom"><p>23F</p></td><td style="vertical-align:bottom"><p>96.6</p></td><td style="vertical-align:bottom"><p>97.9</p></td><td style="vertical-align:bottom"><p>-1.3</p><p>(-3.1, 0.4)</p></td><td style="vertical-align:bottom"><p>3.95</p></td><td style="vertical-align:bottom"><p>6.18</p></td><td style="vertical-align:bottom"><p>0.64</p><p>(0.57, 0.72)</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Additional Serotypes</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>99.2</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>1.4</p><p>(0.1, 2.8)</p></td><td style="vertical-align:bottom"><p>3.97</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>1.87</p><p>(1.71, 2.06)</p></td></tr><tr><td style="vertical-align:bottom"><p>10A</p></td><td style="vertical-align:bottom"><p>98.7</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>0.8</p><p>(-0.5, 2.3)</p></td><td style="vertical-align:bottom"><p>6.22</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>2.94</p><p>(2.64, 3.26)</p></td></tr><tr><td style="vertical-align:bottom"><p>11A</p></td><td style="vertical-align:bottom"><p>98.7</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>0.8</p><p>(-0.5, 2.3)</p></td><td style="vertical-align:bottom"><p>3.53</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>1.67</p><p>(1.51, 1.84)</p></td></tr><tr><td style="vertical-align:bottom"><p>12F</p></td><td style="vertical-align:bottom"><p>86.4</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>-11.5</p><p>(-14.3, -8.9)</p></td><td style="vertical-align:bottom"><p>1.85</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>0.88</p><p>(0.79, 0.97)</p></td></tr><tr><td style="vertical-align:bottom"><p>15B</p></td><td style="vertical-align:bottom"><p>99.6</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>1.8</p><p>(0.7, 3.1)</p></td><td style="vertical-align:bottom"><p>12.59</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>5.95</p><p>(5.39, 6.55)</p></td></tr><tr><td style="vertical-align:bottom"><p>22F</p></td><td style="vertical-align:bottom"><p>99.6</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>1.8</p><p>(0.7, 3.1)</p></td><td style="vertical-align:bottom"><p>10.60</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>5.01</p><p>(4.54, 5.52)</p></td></tr><tr><td style="vertical-align:bottom"><p>33F</p></td><td style="vertical-align:bottom"><p>99.6</p></td><td style="vertical-align:bottom"><p>97.9<sup>f</sup></p></td><td style="vertical-align:bottom"><p>1.8</p><p>(0.7, 3.1)</p></td><td style="vertical-align:bottom"><p>9.31</p></td><td style="vertical-align:bottom"><p>2.12<sup>g</sup></p></td><td style="vertical-align:bottom"><p>4.40</p><p>(3.99, 4.85)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: CI = confidence interval; dLIA = Luminex-based direct immunoassay; ELISA = enzyme-linked immunosorbent assay; GMC = geometric mean concentration; GMR = geometric mean ratio; IgG&nbsp;=&nbsp;immunoglobulin G; LLOQ = lower limit of quantitation.</p><p>Note: Non‑inferiority for a serotype was concluded if the lower bound of the 2-sided 95% CI for the GMR (Prevenar&nbsp;20 to Prevenar 13) was &gt;&nbsp;0.5 for that serotype.<br />Note: Assay results below the LLOQ were set to 0.5 &times; LLOQ in the analysis.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study 1011 was conducted in the United States and the territory of Puerto Rico (NCT04382326).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Specified levels for the Prevenar&nbsp;13 serotypes are from a published bridging study (Tan CY, et al. 2018) using results from after primary infant doses, before toddler dose, and after toddler dose (schedule of 3 infant doses followed by a toddler dose) except for serotype 19A, which used results from after primary infant doses only. For the additional 7 serotypes, specified levels are from a concordance evaluation (clinical dLIA to re-test ELISA) of data from a Phase 2 Study B7471003, which also uses the schedule of 3 infant doses followed by a toddler dose.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N = Number of participants with valid IgG concentrations.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two-sided CI based on the Miettinen and Nurminen method.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GMCs, GMRs and the associated 2-sided CIs were calculated by exponentiating the means and the mean differences (Prevenar&nbsp;20 &ndash; Prevenar 13) of the logarithm of the concentrations and the corresponding CIs (based on the Student&rsquo;s t distribution).</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the percentage differences of the 7 additional serotypes, the IgG results from serotype 18C or 23F (Prevenar 13 serotype with the lowest percentage excluding serotype 3) in the Prevenar&nbsp;13 group was used in the comparisons for non‑inferiority. Percentages of participants with specified IgG concentrations to serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F in the Prevenar 13 group were 4.2%, 2.2%, 3.8%, 0.1%, 3.1%, 1.7% and 2.3%, respectively.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the GMRs of the 7 additional serotypes, the IgG results from serotype 1 (Prevenar&nbsp;13 serotype with the lowest GMC excluding serotype 3) in the Prevenar 13 group was used in the comparisons for non‑inferiority. IgG GMCs to serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F in the Prevenar 13 group were 0.03 &micro;g/mL, 0.01 &micro;g/mL, 0.02 &micro;g/mL, 0.01 &micro;g/mL, 0.02 &micro;g/mL, 0.00 &micro;g/mL and 0.01 &micro;g/mL, respectively.</p></td></tr></tbody></table><p>&nbsp;</p><p>OPA GMTs for the 13 matched serotypes in the Prevenar&nbsp;20 group were generally comparable to the OPA GMTs in the Prevenar&nbsp;13 group 1 month after the third infant dose, and they were slightly lower than in the Prevenar 13 group for most serotypes after the toddler dose. There is variability of the OPA data due to small sample sizes, while interpretation of the clinical relevance of slightly lower OPA GMTs is unknown. The observed OPA GMTs for the 7 additional serotypes were substantially higher in the Prevenar&nbsp;20 group than the Prevenar&nbsp;13 group. Prevenar&nbsp;20 immune responses also show boosting of IgG concentrations and OPA GMTs after the toddler dose, indicating that a memory response was elicited by the 3&nbsp;infant doses.&nbsp;</p><p>&nbsp;</p><p><em>Pneumococcal IgG immune responses following 2 and 3&nbsp;doses of 3-dose vaccination series</em></p><p><em>&nbsp;</em></p><p>In Study 1012, 1,204 infants 2&nbsp;months (&ge;&nbsp;42 to &le;&nbsp;112&nbsp;days) of age at the time of consent and born at &gt;&nbsp;36&nbsp;weeks of gestation were randomised (1:1) and vaccinated with either Prevenar&nbsp;20 or Prevenar&nbsp;13. The first dose was given at enrollment, a second dose approximately 2&nbsp;months later, and the third dose at approximately 11 to 12&nbsp;months of age.</p><p>&nbsp;</p><p>One month after 2 infant doses, the observed IgG GMCs for 9 of the 13 matched serotypes were non-inferior to those in the Prevenar 13 group, and 4 of the 13 matched serotypes (6A, 6B, 9V, and 23F) did not meet the 2-fold statistical criterion for non‑inferiority. The percentages of participants with specified serotype-specific IgG concentrations 1 month after Dose 2 of Prevenar&nbsp;20 for 4 of the 13 matched serotypes were non-inferior to those of the Prevenar 13 group based on a 10% difference non‑inferiority criteria; and 9 of the 13 matched serotypes (1, 3, 4, 5, 6A, 6B, 9V, 18C and 23F) did not meet noninferiority.</p><p>&nbsp;</p><p>The immune responses to the additional 7 serotypes after Prevenar&nbsp;20 were non-inferior to the lowest IgG GMC among the 13 serotypes (serotype 6B) in Prevenar 13. For the 7 additional serotypes, the percentages of participants with specified serotype-specific IgG concentrations 1 month after Dose 2 of Prevenar&nbsp;20 for 5 of the 7 additional serotypes were non-inferior to the serotype with the lowest percentage among the 13 serotypes (serotype 6B) in the Prevenar 13 group and serotypes 10A and 12F did not meet the statistical noninferiority criterion. The clinical relevance of these findings is unknown. Additionally, the IgG GMCs for the 7 additional serotypes were higher compared with the IgG GMCs from the corresponding serotypes in the Prevenar 13 group after two infant doses. One month after the third (toddler) dose, the observed IgG GMCs of Prevenar&nbsp;20 were non-inferior to the Prevenar 13 group for 12 of 13 matched serotypes except for serotype 6B and all 7 additional serotypes were non-inferior to the lowest IgG GMC in the Prevenar 13 group. Additionally, the IgG GMCs for the 7 additional serotypes were higher compared with the IgG GMCs from the corresponding serotypes in the Prevenar 13 group after the toddler dose.</p><p>&nbsp;</p><p>Functional responses, as measured by OPA GMTs, for the 13 matched serotypes at 1 month after the second infant dose and 1 month after the toddler dose in the Prevenar&nbsp;20 group were generally similar to the observed OPA GMTs in the Prevenar 13 group for most serotypes and the observed OPA GMTs were substantially higher for the 7 additional serotypes at both timepoints in the Prevenar&nbsp;20 group than in the Prevenar 13 group. Increases in IgG and OPA antibody responses after Prevenar&nbsp;20 following Dose 2 to after Dose 3 were observed for all 20 serotypes including those that missed non‑inferiority, indicative of immunological memory.</p><p>&nbsp;</p><p><em>Children and adolescents 15&nbsp;months to less than 18&nbsp;years of age (Study 1014)</em></p><p>&nbsp;</p><p>In a multicenter, single-arm trial (Study 1014), participants were enrolled into the study by age group (approximately 200&nbsp;participants per group) to receive a single dose of Prevenar&nbsp;20 as described below.</p><p><em>&nbsp;</em></p><p>Children 15&nbsp;months to less than 24 months of age previously vaccinated with Prevenar&nbsp;13</p><p>&nbsp;</p><p>In 15&nbsp;months to less than 24&nbsp;months age group, participants had been previously vaccinated with 3 or 4 doses of Prevenar 13. Increases in IgG concentrations from before to 1&nbsp;month after Prevenar&nbsp;20 were observed for all 20&nbsp;vaccine serotypes. The observed IgG geometric mean fold rises (GMFRs) to the 7 additional serotypes ranged from 27.9 to 1847.7.</p><p>&nbsp;</p><p><em>Children 24&nbsp;months to less than 5 years of age previously vaccinated with Prevenar 13</em></p><p>&nbsp;</p><p>In 24 months to less than 5 years age group, participants had been previously vaccinated with 3 or 4 doses of Prevenar 13. Increases in IgG concentrations from before to 1&nbsp;month after Prevenar&nbsp;20 were observed for all 20&nbsp;vaccine serotypes. The observed IgG GMFRs to the 7 additional serotypes ranged from 36.6 to 796.2. For the 7 additional serotypes, 71.2% to 94.6% had &ge;&nbsp;4-fold rise in OPA titres.</p><p>&nbsp;</p><p>Children and adolescents 5&nbsp;years to less than 18&nbsp;years of age previously unvaccinated or vaccinated with Prevenar&nbsp;13</p><p>&nbsp;</p><p>In participants 5 years to less than 10&nbsp;years and 10 years to less than 18&nbsp;years of age, irrespective of prior vaccination history with Prevenar&nbsp;13. Prevenar&nbsp;20 elicited robust IgG and OPA immune responses to the 20 vaccine serotypes after a single dose in participants 5&nbsp;to less than 18&nbsp;years of age. OPA GMFRs ranged from 11.5 to 499.0 to the 7 additional serotypes and increases in OPA GMTs were observed for all 20 vaccine serotypes.</p><p>&nbsp;</p><p><em>Preterm infants</em></p><p>&nbsp;</p><p>No immunogenicity data is available with Prevenar&nbsp;20 in preterm infants. Based on experience with Prevenar and Prevenar&nbsp;13, immune responses are elicited in preterm infants, although they may be lower than in term infants. The safety and tolerability of Prevenar&nbsp;20 were evaluated in Phase 3 study (Study 1013), which included 111 late preterm infants (infants born at 34 to less than 37&nbsp;weeks of gestational age) among the total study population. Participants were randomised to receive a 4-dose series of either Prevenar&nbsp;20 (N=77) or Prevenar&nbsp;13 (N=34).</p><p><strong>&nbsp;</strong></p><p><em>Prevenar&nbsp;20 clinical trials in adults</em></p><p>&nbsp;</p><p>Three Phase 3 clinical trials, B7471006, B7471007 and B7471008 (Study&nbsp;1006, Study&nbsp;1007, and Study&nbsp;1008), were conducted in the United States and Sweden evaluating the immunogenicity of Prevenar&nbsp;20 in different adult age groups, and in participants who were either pneumococcal vaccine‑na&iuml;ve, or previously vaccinated with Prevenar&nbsp;13, PPSV23, or both.</p><p>&nbsp;</p><p>Each study included participants who were healthy or immunocompetent with stable underlying conditions, including chronic cardiovascular disease, chronic pulmonary disease, renal disorders, diabetes mellitus, chronic liver disease, and medical risk conditions and behaviours (e.g.,&nbsp;smoking) that are known to increase the risk of serious pneumococcal pneumonia and IPD. In the pivotal study (Study&nbsp;1007), these risk factors were identified in 34%, 32%, and 26% of participants 60&nbsp;years of age and over, 50 to 59&nbsp;years of age, and 18 to 49&nbsp;years of age, respectively. A stable medical condition was defined as a medical condition not requiring significant change in therapy in the previous 6&nbsp;weeks (i.e., change to new therapy category due to worsening disease), or any hospitalization for worsening disease within 12&nbsp;weeks before receiving the study vaccine.</p><p>&nbsp;</p><p>In each study, immune responses elicited by Prevenar&nbsp;20 and the control pneumococcal vaccines were measured by an opsonophagocytic activity (OPA) assay. OPA assays measure functional antibodies to <em>S.&nbsp;pneumoniae</em>.</p><p>&nbsp;</p><p><em>Comparison of immune responses of </em><em>Prevenar&nbsp;20</em><em> to Prevenar&nbsp;13 and PPSV23</em></p><p>&nbsp;</p><p>In a randomised, active-controlled, double-blind, non‑inferiority clinical trial (Pivotal Study&nbsp;1007) of Prevenar&nbsp;20 in the United States and Sweden, pneumococcal vaccine‑na&iuml;ve participants 18&nbsp;years of age and older were enrolled into 1 of 3 cohorts based on their age at enrollment (18 to 49, 50 to 59, and &ge;&nbsp;60&nbsp;years of age), and randomised to receive Prevenar&nbsp;20 or control. Participants 60&nbsp;years of age and older were randomised in a 1:1&nbsp;ratio to receive Prevenar&nbsp;20 (n = 1,507) followed 1&nbsp;month later with the administration of saline placebo or Prevenar&nbsp;13 (n = 1,490), and with the administration of PPSV23 1&nbsp;month later. Participants 18 to 49&nbsp;years of age and 50&nbsp;to&nbsp;59&nbsp;years of age were randomly assigned (3:1 ratio); they received a dose of Prevenar&nbsp;20 (18&nbsp;to&nbsp;49&nbsp;years of age: n = 335; 50&nbsp;to&nbsp;59&nbsp;years of age: n&nbsp;=&nbsp;334) or Prevenar&nbsp;13 (18&nbsp;to 49&nbsp;years of age: n = 112; 50&nbsp;to&nbsp;59&nbsp;years of age: n = 111).</p><p>&nbsp;</p><p>Serotype-specific OPA GMTs were measured before the first vaccination and 1&nbsp;month after each vaccination. Non‑inferiority of immune responses, OPA GMTs 1&nbsp;month after vaccination, with Prevenar&nbsp;20 to a control vaccine for a serotype was declared if the lower bound of the 2‑sided 95% CI for the GMT ratio (Prevenar&nbsp;20/Prevenar&nbsp;13; Prevenar&nbsp;20/PPSV23) for that serotype was greater than 0.5.</p><p>&nbsp;</p><p>In participants 60&nbsp;years of age and older, the immune responses to all 13 matched serotypes elicited by Prevenar&nbsp;20 were non‑inferior to those elicited by Prevenar&nbsp;13 for the same serotypes 1&nbsp;month after vaccination. In general, numerically lower geometric mean titres were observed with Prevenar&nbsp;20 in the matched serotypes compared to Prevenar 13 (Table 5), however the clinical relevance of these findings is unknown.</p><p>&nbsp;</p><p>The immune responses induced by Prevenar&nbsp;20 to 6/7&nbsp;additional serotypes were non‑inferior to those induced by PPSV23 to the same serotypes 1 month after vaccination. The response to serotype 8 missed the pre-specified statistical non‑inferiority criterion (the lower bound of the 2‑sided 95%&nbsp;CI for the GMT ratio is 0.49 instead of &gt;&nbsp;0.50) (Table&nbsp;5). The clinical relevance of this observation is unknown. Supportive analyses for other serotype 8 endpoints in the Prevenar&nbsp;20 group showed favourable outcomes. These include a GMFR of 22.1 from before vaccination to 1&nbsp;month post‑vaccination, 77.8% of participants achieved a &ge;&nbsp;4-fold rise in OPA titres from before vaccination to 1&nbsp;month after vaccination, and 92.9% of participants achieved OPA titres &ge;&nbsp;LLOQ 1&nbsp;month after vaccination.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 5.&nbsp;&nbsp;&nbsp;&nbsp; OPA GMTs 1 Month After Vaccination in Participants 60&nbsp;Years of Age and Older Given </strong><strong>Prevenar&nbsp;20 Compared to Prevenar&nbsp;13 for the 13&nbsp;Matched Serotypes and to PPSV23 for the 7&nbsp;Additional Serotypes (Study 1007)<sup>a,b,c,d </sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;20</strong></p><p><strong>(N = 1157&ndash;1430)</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;13</strong></p><p><strong>(N = 1390&ndash;1419)</strong></p></td><td style="vertical-align:bottom"><p><strong>PPSV23</strong></p><p><strong>(N = 1201&ndash;1319)</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Vaccine Comparison</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT Ratio<sup>e</sup></strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>95% CI<sup>e</sup></strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Serotype</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:bottom"><p>123</p></td><td style="vertical-align:bottom"><p>154</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.80</p></td><td colspan="2" style="vertical-align:top"><p>0.71, 0.90</p></td></tr><tr><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>41</p></td><td style="vertical-align:bottom"><p>48</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.85</p></td><td colspan="2" style="vertical-align:top"><p>0.78, 0.93</p></td></tr><tr><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>509</p></td><td style="vertical-align:bottom"><p>627</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.81</p></td><td colspan="2" style="vertical-align:top"><p>0.71, 0.93</p></td></tr><tr><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>92</p></td><td style="vertical-align:bottom"><p>110</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.83</p></td><td colspan="2" style="vertical-align:top"><p>0.74, 0.94</p></td></tr><tr><td style="vertical-align:bottom"><p>6A</p></td><td style="vertical-align:bottom"><p>889</p></td><td style="vertical-align:bottom"><p>1165</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.76</p></td><td colspan="2" style="vertical-align:top"><p>0.66, 0.88</p></td></tr><tr><td style="vertical-align:bottom"><p>6B</p></td><td style="vertical-align:bottom"><p>1115</p></td><td style="vertical-align:bottom"><p>1341</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.83</p></td><td colspan="2" style="vertical-align:top"><p>0.73, 0.95</p></td></tr><tr><td style="vertical-align:bottom"><p>7F</p></td><td style="vertical-align:bottom"><p>969</p></td><td style="vertical-align:bottom"><p>1129</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.86</p></td><td colspan="2" style="vertical-align:top"><p>0.77, 0.96</p></td></tr><tr><td style="vertical-align:bottom"><p>9V</p></td><td style="vertical-align:bottom"><p>1456</p></td><td style="vertical-align:bottom"><p>1568</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.93</p></td><td colspan="2" style="vertical-align:top"><p>0.82, 1.05</p></td></tr><tr><td style="vertical-align:bottom"><p>14</p></td><td style="vertical-align:bottom"><p>747</p></td><td style="vertical-align:bottom"><p>747</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.00</p></td><td colspan="2" style="vertical-align:top"><p>0.89, 1.13</p></td></tr><tr><td style="vertical-align:bottom"><p>18C</p></td><td style="vertical-align:bottom"><p>1253</p></td><td style="vertical-align:bottom"><p>1482</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.85</p></td><td colspan="2" style="vertical-align:top"><p>0.74, 0.97</p></td></tr><tr><td style="vertical-align:bottom"><p>19A</p></td><td style="vertical-align:bottom"><p>518</p></td><td style="vertical-align:bottom"><p>645</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.80</p></td><td colspan="2" style="vertical-align:top"><p>0.71, 0.90</p></td></tr><tr><td style="vertical-align:bottom"><p>19F</p></td><td style="vertical-align:bottom"><p>266</p></td><td style="vertical-align:bottom"><p>333</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.80</p></td><td colspan="2" style="vertical-align:top"><p>0.70, 0.91</p></td></tr><tr><td style="vertical-align:bottom"><p>23F</p></td><td style="vertical-align:bottom"><p>277</p></td><td style="vertical-align:bottom"><p>335</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.83</p></td><td colspan="2" style="vertical-align:top"><p>0.70, 0.97</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Additional Serotypes</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>466</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>848</p></td><td style="vertical-align:bottom"><p>0.55</p></td><td colspan="2" style="vertical-align:bottom"><p>0.49, 0.62</p></td></tr><tr><td style="vertical-align:bottom"><p>10A</p></td><td style="vertical-align:bottom"><p>2008</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>1080</p></td><td style="vertical-align:bottom"><p>1.86</p></td><td colspan="2" style="vertical-align:bottom"><p>1.63, 2.12</p></td></tr><tr><td style="vertical-align:bottom"><p>11A</p></td><td style="vertical-align:bottom"><p>4427</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>2535</p></td><td style="vertical-align:bottom"><p>1.75</p></td><td colspan="2" style="vertical-align:bottom"><p>1.52, 2.01</p></td></tr><tr><td style="vertical-align:bottom"><p>12F</p></td><td style="vertical-align:bottom"><p>2539</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>1717</p></td><td style="vertical-align:bottom"><p>1.48</p></td><td colspan="2" style="vertical-align:bottom"><p>1.27, 1.72</p></td></tr><tr><td style="vertical-align:bottom"><p>15B</p></td><td style="vertical-align:bottom"><p>2398</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>769</p></td><td style="vertical-align:bottom"><p>3.12</p></td><td colspan="2" style="vertical-align:bottom"><p>2.62, 3.71</p></td></tr><tr><td style="vertical-align:bottom"><p>22F</p></td><td style="vertical-align:bottom"><p>3666</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>1846</p></td><td style="vertical-align:bottom"><p>1.99</p></td><td colspan="2" style="vertical-align:bottom"><p>1.70, 2.32</p></td></tr><tr><td style="vertical-align:bottom"><p>33F</p></td><td style="vertical-align:bottom"><p>5126</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>3721</p></td><td style="vertical-align:bottom"><p>1.38</p></td><td colspan="2" style="vertical-align:bottom"><p>1.21, 1.57</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Abbreviations: CI = confidence interval; GMT = geometric mean titre; LLOQ = lower limit of quantitation; N&nbsp;=&nbsp;number of participants; OPA&nbsp;=&nbsp;opsonophagocytic activity; PPSV23&nbsp;=&nbsp;pneumococcal polysaccharide vaccine (23-valent).</p><p>a.&nbsp;&nbsp; Study 1007 was conducted in the United States and in Sweden.</p><p>b.&nbsp;&nbsp; Non‑inferiority for a serotype was met if the lower bound of the 2-sided 95% CI for the GMT ratio (ratio of Prevenar&nbsp;20/comparator) was greater than 0.5 (2-fold criterion for non‑inferiority).</p><p>c.&nbsp;&nbsp; Assay results below the LLOQ were set to 0.5 &times; LLOQ in the analysis.</p><p>d.&nbsp;&nbsp; Evaluable immunogenicity population.</p><p>e.&nbsp;&nbsp; GMTs and GMT ratios as well as the associated 2-sided CIs were based on analysis of log-transformed OPA titres using a regression model with vaccine group, sex, smoking status, age at vaccination in years, and baseline log transformed OPA titres.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Immunogenicity in participants 18 through 59&nbsp;years of age</em></p><p>&nbsp;</p><p>In Study 1007, participants 50&nbsp;through 59&nbsp;years of age and participants 18 through 49&nbsp;years of age were randomly assigned (3:1&nbsp;ratio) to receive 1 vaccination with Prevenar&nbsp;20 or Prevenar&nbsp;13. Serotype‑specific OPA GMTs were measured before vaccination and 1&nbsp;month after vaccination. With both vaccines, higher immune responses were observed in younger participants compared with older participants. A non‑inferiority analysis of Prevenar&nbsp;20 in the younger age group versus Prevenar&nbsp;20 in participants 60 through 64&nbsp;years of age per serotype was performed to support the indication in adults 18 through 49&nbsp;years of age and 50 through 59&nbsp;years of age. Non‑inferiority was declared if the lower bound of the 2‑sided 95% CI for the GMT ratio (Prevenar&nbsp;20 in participants 18 through 49&nbsp;years of age / 60 through 64&nbsp;years of age and in 50&nbsp;through 59&nbsp;years of age / 60 through 64&nbsp;years of age) for each of the 20&nbsp;serotypes was &gt;&nbsp;0.5. Prevenar&nbsp;20 elicited immune responses to all 20 vaccine serotypes in the two of the younger age groups that were non‑inferior to responses in participants 60 through 64&nbsp;years of age 1&nbsp;month after vaccination (Table&nbsp;6).</p><p>&nbsp;</p><p>While not planned as an active control for immunogenicity evaluations in the study, a post hoc descriptive analysis showed generally numerically lower OPA GMTs 1&nbsp;month after Prevenar&nbsp;20 for the matched serotypes compared to Prevenar 13 in participants 18 through 59&nbsp;years of age, however the clinical relevance of these findings is unknown.</p><p>&nbsp;</p><p>As noted above, individuals with risk factors were included in this study. Across all the age groups studied, in general, a numerically lower immune response was observed in participants with risk factors compared to participants without risk factors. The clinical relevance of this observation is unknown.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 6.</strong>&nbsp;&nbsp;&nbsp;&nbsp; <strong>Comparisons of OPA GMTs 1&nbsp;Month After Prevenar&nbsp;20 in Participants 18 Through 49&nbsp;or 50 Through 59&nbsp;Years of Age to Participants 60 Through 64&nbsp;Years of Age (Study&nbsp;1007)<sup>a,b,c,d </sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>18&ndash;49&nbsp;Years</strong></p><p><strong>(N = 251&ndash;317)</strong></p></td><td style="vertical-align:bottom"><p><strong>60&ndash;64&nbsp;Years</strong></p><p><strong>(N = 765&ndash;941)</strong></p></td><td style="vertical-align:bottom"><p><strong>18&ndash;49&nbsp;Years</strong></p><p><strong>Relative to </strong></p><p><strong>60&ndash;64&nbsp;Years</strong></p></td><td style="vertical-align:bottom"><p><strong>50&ndash;59&nbsp;Years</strong></p><p><strong>(N = 266&ndash;320)</strong></p></td><td style="vertical-align:bottom"><p><strong>60&ndash;64&nbsp;Years</strong></p><p><strong>(N = 765&ndash;941)</strong></p></td><td style="vertical-align:bottom"><p><strong>50&ndash;59&nbsp;Years</strong></p><p><strong>Relative to </strong></p><p><strong>60&ndash;64&nbsp;Years</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT Ratio<sup>e</sup></strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT Ratio<sup>e</sup></strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Serotype</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:bottom"><p>163</p></td><td style="vertical-align:bottom"><p>132</p></td><td style="vertical-align:bottom"><p>1.23</p><p>(1.01, 1.50)</p></td><td style="vertical-align:bottom"><p>136</p></td><td style="vertical-align:bottom"><p>132</p></td><td style="vertical-align:bottom"><p>1.03</p><p>(0.84, 1.26)</p></td></tr><tr><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>42</p></td><td style="vertical-align:bottom"><p>42</p></td><td style="vertical-align:bottom"><p>1.00</p><p>(0.87, 1.16)</p></td><td style="vertical-align:bottom"><p>43</p></td><td style="vertical-align:bottom"><p>41</p></td><td style="vertical-align:bottom"><p>1.06</p><p>(0.92, 1.22)</p></td></tr><tr><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>1967</p></td><td style="vertical-align:bottom"><p>594</p></td><td style="vertical-align:bottom"><p>3.31</p><p>(2.65, 4.13)</p></td><td style="vertical-align:bottom"><p>633</p></td><td style="vertical-align:bottom"><p>578</p></td><td style="vertical-align:bottom"><p>1.10</p><p>(0.87, 1.38)</p></td></tr><tr><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>108</p></td><td style="vertical-align:bottom"><p>97</p></td><td style="vertical-align:bottom"><p>1.11</p><p>(0.91, 1.36)</p></td><td style="vertical-align:bottom"><p>85</p></td><td style="vertical-align:bottom"><p>97</p></td><td style="vertical-align:bottom"><p>0.88</p><p>(0.72, 1.07)</p></td></tr><tr><td style="vertical-align:bottom"><p>6A</p></td><td style="vertical-align:bottom"><p>3931</p></td><td style="vertical-align:bottom"><p>1023</p></td><td style="vertical-align:bottom"><p>3.84</p><p>(3.06, 4.83)</p></td><td style="vertical-align:bottom"><p>1204</p></td><td style="vertical-align:bottom"><p>997</p></td><td style="vertical-align:bottom"><p>1.21</p><p>(0.95, 1.53)</p></td></tr><tr><td style="vertical-align:bottom"><p>6B</p></td><td style="vertical-align:bottom"><p>4260</p></td><td style="vertical-align:bottom"><p>1250</p></td><td style="vertical-align:bottom"><p>3.41</p><p>(2.73, 4.26)</p></td><td style="vertical-align:bottom"><p>1503</p></td><td style="vertical-align:bottom"><p>1199</p></td><td style="vertical-align:bottom"><p>1.25</p><p>(1.00, 1.56)</p></td></tr><tr><td style="vertical-align:bottom"><p>7F</p></td><td style="vertical-align:bottom"><p>1873</p></td><td style="vertical-align:bottom"><p>1187</p></td><td style="vertical-align:bottom"><p>1.58</p><p>(1.30, 1.91)</p></td><td style="vertical-align:bottom"><p>1047</p></td><td style="vertical-align:bottom"><p>1173</p></td><td style="vertical-align:bottom"><p>0.89</p><p>(0.74, 1.07)</p></td></tr><tr><td style="vertical-align:bottom"><p>9V</p></td><td style="vertical-align:bottom"><p>6041</p></td><td style="vertical-align:bottom"><p>1727</p></td><td style="vertical-align:bottom"><p>3.50</p><p>(2.83, 4.33)</p></td><td style="vertical-align:bottom"><p>1726</p></td><td style="vertical-align:bottom"><p>1688</p></td><td style="vertical-align:bottom"><p>1.02</p><p>(0.83, 1.26)</p></td></tr><tr><td style="vertical-align:bottom"><p>14</p></td><td style="vertical-align:bottom"><p>1848</p></td><td style="vertical-align:bottom"><p>773</p></td><td style="vertical-align:bottom"><p>2.39</p><p>(1.93, 2.96)</p></td><td style="vertical-align:bottom"><p>926</p></td><td style="vertical-align:bottom"><p>742</p></td><td style="vertical-align:bottom"><p>1.25</p><p>(1.01, 1.54)</p></td></tr><tr><td style="vertical-align:bottom"><p>18C</p></td><td style="vertical-align:bottom"><p>4460</p></td><td style="vertical-align:bottom"><p>1395</p></td><td style="vertical-align:bottom"><p>3.20</p><p>(2.53, 4.04)</p></td><td style="vertical-align:bottom"><p>1805</p></td><td style="vertical-align:bottom"><p>1355</p></td><td style="vertical-align:bottom"><p>1.33</p><p>(1.06, 1.68)</p></td></tr><tr><td style="vertical-align:bottom"><p>19A</p></td><td style="vertical-align:bottom"><p>1415</p></td><td style="vertical-align:bottom"><p>611</p></td><td style="vertical-align:bottom"><p>2.31</p><p>(1.91, 2.81)</p></td><td style="vertical-align:bottom"><p>618</p></td><td style="vertical-align:bottom"><p>600</p></td><td style="vertical-align:bottom"><p>1.03</p><p>(0.85, 1.25)</p></td></tr><tr><td style="vertical-align:bottom"><p>19F</p></td><td style="vertical-align:bottom"><p>655</p></td><td style="vertical-align:bottom"><p>301</p></td><td style="vertical-align:bottom"><p>2.17</p><p>(1.76, 2.68)</p></td><td style="vertical-align:bottom"><p>287</p></td><td style="vertical-align:bottom"><p>290</p></td><td style="vertical-align:bottom"><p>0.99</p><p>(0.80, 1.22)</p></td></tr><tr><td style="vertical-align:bottom"><p>23F</p></td><td style="vertical-align:bottom"><p>1559</p></td><td style="vertical-align:bottom"><p>325</p></td><td style="vertical-align:bottom"><p>4.80</p><p>(3.65, 6.32)</p></td><td style="vertical-align:bottom"><p>549</p></td><td style="vertical-align:bottom"><p>328</p></td><td style="vertical-align:bottom"><p>1.68</p><p>(1.27, 2.22)</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Additional Serotypes</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>867</p></td><td style="vertical-align:bottom"><p>508</p></td><td style="vertical-align:bottom"><p>1.71</p><p>(1.38, 2.12)</p></td><td style="vertical-align:bottom"><p>487</p></td><td style="vertical-align:bottom"><p>502</p></td><td style="vertical-align:bottom"><p>0.97</p><p>(0.78, 1.20)</p></td></tr><tr><td style="vertical-align:bottom"><p>10A</p></td><td style="vertical-align:bottom"><p>4157</p></td><td style="vertical-align:bottom"><p>2570</p></td><td style="vertical-align:bottom"><p>1.62</p><p>(1.31, 2.00)</p></td><td style="vertical-align:bottom"><p>2520</p></td><td style="vertical-align:bottom"><p>2437</p></td><td style="vertical-align:bottom"><p>1.03</p><p>(0.84, 1.28)</p></td></tr><tr><td style="vertical-align:bottom"><p>11A</p></td><td style="vertical-align:bottom"><p>7169</p></td><td style="vertical-align:bottom"><p>5420</p></td><td style="vertical-align:bottom"><p>1.32</p><p>(1.04, 1.68)</p></td><td style="vertical-align:bottom"><p>6417</p></td><td style="vertical-align:bottom"><p>5249</p></td><td style="vertical-align:bottom"><p>1.22</p><p>(0.96, 1.56)</p></td></tr><tr><td style="vertical-align:bottom"><p>12F</p></td><td style="vertical-align:bottom"><p>5875</p></td><td style="vertical-align:bottom"><p>3075</p></td><td style="vertical-align:bottom"><p>1.91</p><p>(1.51, 2.41)</p></td><td style="vertical-align:bottom"><p>3445</p></td><td style="vertical-align:bottom"><p>3105</p></td><td style="vertical-align:bottom"><p>1.11</p><p>(0.88, 1.39)</p></td></tr><tr><td style="vertical-align:bottom"><p>15B</p></td><td style="vertical-align:bottom"><p>4601</p></td><td style="vertical-align:bottom"><p>3019</p></td><td style="vertical-align:bottom"><p>1.52</p><p>(1.13, 2.05)</p></td><td style="vertical-align:bottom"><p>3356</p></td><td style="vertical-align:bottom"><p>2874</p></td><td style="vertical-align:bottom"><p>1.17</p><p>(0.88, 1.56)</p></td></tr><tr><td style="vertical-align:bottom"><p>22F</p></td><td style="vertical-align:bottom"><p>7568</p></td><td style="vertical-align:bottom"><p>4482</p></td><td style="vertical-align:bottom"><p>1.69</p><p>(1.30, 2.20)</p></td><td style="vertical-align:bottom"><p>3808</p></td><td style="vertical-align:bottom"><p>4228</p></td><td style="vertical-align:bottom"><p>0.90</p><p>(0.69, 1.17)</p></td></tr><tr><td style="vertical-align:bottom"><p>33F</p></td><td style="vertical-align:bottom"><p>7977</p></td><td style="vertical-align:bottom"><p>5693</p></td><td style="vertical-align:bottom"><p>1.40</p><p>(1.10, 1.79)</p></td><td style="vertical-align:bottom"><p>5571</p></td><td style="vertical-align:bottom"><p>5445</p></td><td style="vertical-align:bottom"><p>1.02</p><p>(0.81, 1.30)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: CI = confidence interval; GMT = geometric mean titre; LLOQ = lower limit of quantitation; N&nbsp;=&nbsp;number of participants; OPA&nbsp;=&nbsp;opsonophagocytic activity; PPSV23&nbsp;= pneumococcal polysaccharide vaccine (23-valent).</p><p>a.&nbsp;&nbsp; Study 1007 was conducted in the United States and in Sweden.</p><p>b.&nbsp;&nbsp; Non‑inferiority for a serotype was met if the lower bound of the 2-sided 95% CI for the GMT ratio (ratio of younger age group/60&nbsp;through 64&nbsp;years of age group) was greater than 0.5 (2-fold criterion for non‑inferiority).</p><p>c.&nbsp;&nbsp; Assay results below the LLOQ were set to 0.5 &times; LLOQ in the analysis.</p><p>d.&nbsp;&nbsp; Evaluable immunogenicity population.</p><p>e.&nbsp;&nbsp; GMTs, GMT ratios, and the associated 2-sided CIs were based on analysis of log-transformed OPA titres using a regression model with age group, sex, smoking status, and baseline log transformed OPA titres. The comparisons between participants 18 through 49&nbsp;years of age and participants 60 through 64&nbsp;years of age and between participants 50 through 59&nbsp;years of age and participants 60 through 64&nbsp;years of age were based on separate regression models.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Immunogenicity of </em><em>Prevenar&nbsp;20</em><em> in adults previously vaccinated with pneumococcal vaccine </em></p><p>&nbsp;</p><p>A Phase 3 randomised, open-label clinical trial (Study 1006) described immune responses to Prevenar&nbsp;20 in participants 65&nbsp;years of age and older previously vaccinated with PPSV23, with Prevenar&nbsp;13, or with Prevenar&nbsp;13 followed by PPSV23. Participants previously vaccinated with Prevenar&nbsp;13 (Prevenar&nbsp;13 only or followed by PPSV23) were enrolled at sites in the United&nbsp;States, whereas participants and previously vaccinated with PPSV23 only were also enrolled from Swedish sites (35.5% in that category).</p><p>&nbsp;</p><p>Prevenar&nbsp;20 elicited immune responses to all 20 vaccine serotypes in participants 65&nbsp;years of age and older with prior pneumococcal vaccination (Table&nbsp;7). Immune responses were lower in participants in both groups who received prior PPSV23 vaccinations.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 7.</strong>&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pneumococcal OPA GMTs Before and 1 Month After </strong><strong>Prevenar&nbsp;20 in Participants 65&nbsp;Years of Age and Older With Prior Pneumococcal Vaccination (Study 1006)<sup>a,b,c,d </sup></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Prior PPSV23 only</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Prior Prevenar&nbsp;13 only</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Prior Prevenar&nbsp;13 and PPSV23</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Before vaccination</strong></p><p><strong>(N = 208&ndash;247)</strong></p></td><td style="vertical-align:bottom"><p><strong>After vaccination</strong></p><p><strong>(N = 216&ndash;246)</strong></p></td><td style="vertical-align:bottom"><p><strong>Before vaccination</strong></p><p><strong>(N = 210-243)</strong></p></td><td style="vertical-align:bottom"><p><strong>After vaccination</strong></p><p><strong>(N = 201&ndash;243)</strong></p></td><td style="vertical-align:bottom"><p><strong>Before vaccination</strong></p><p><strong>(N = 106&ndash;121)</strong></p></td><td style="vertical-align:bottom"><p><strong>After vaccination</strong></p><p><strong>(N = 102-121)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>GMT</strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT</strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT</strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT</strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT</strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>GMT</strong></p><p><strong>(95% CI)<sup>e</sup></strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Serotype</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:top"><p>24</p><p>(20, 28)</p></td><td style="vertical-align:top"><p>51</p><p>(42, 62)</p></td><td style="vertical-align:top"><p>34</p><p>(28, 41)</p></td><td style="vertical-align:top"><p>115</p><p>(96, 138)</p></td><td style="vertical-align:top"><p>42</p><p>(32, 56)</p></td><td style="vertical-align:top"><p>82</p><p>(61, 110)</p></td></tr><tr><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:top"><p>13</p><p>(11, 15)</p></td><td style="vertical-align:top"><p>31</p><p>(27, 36)</p></td><td style="vertical-align:top"><p>15</p><p>(13, 18)</p></td><td style="vertical-align:top"><p>54</p><p>(47, 63)</p></td><td style="vertical-align:top"><p>20</p><p>(17, 25)</p></td><td style="vertical-align:top"><p>39</p><p>(32, 48)</p></td></tr><tr><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:top"><p>29</p><p>(23, 35)</p></td><td style="vertical-align:top"><p>150</p><p>(118, 190)</p></td><td style="vertical-align:top"><p>67</p><p>(53, 84)</p></td><td style="vertical-align:top"><p>335</p><p>(274, 410)</p></td><td style="vertical-align:top"><p>73</p><p>(53, 101)</p></td><td style="vertical-align:top"><p>194</p><p>(143, 262)</p></td></tr><tr><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:top"><p>27</p><p>(24, 31)</p></td><td style="vertical-align:top"><p>63</p><p>(53, 75)</p></td><td style="vertical-align:top"><p>38</p><p>(32, 44)</p></td><td style="vertical-align:top"><p>87</p><p>(73, 104)</p></td><td style="vertical-align:top"><p>47</p><p>(37, 59)</p></td><td style="vertical-align:top"><p>83</p><p>(65, 108)</p></td></tr><tr><td style="vertical-align:bottom"><p>6A</p></td><td style="vertical-align:top"><p>57</p><p>(46, 70)</p></td><td style="vertical-align:top"><p>749</p><p>(577, 972)</p></td><td style="vertical-align:top"><p>125</p><p>(99, 158)</p></td><td style="vertical-align:top"><p>1081</p><p>(880, 1327)</p></td><td style="vertical-align:top"><p>161</p><p>(116, 224)</p></td><td style="vertical-align:top"><p>1085</p><p>(797, 1478)</p></td></tr><tr><td style="vertical-align:bottom"><p>6B</p></td><td style="vertical-align:top"><p>107</p><p>(86, 133)</p></td><td style="vertical-align:top"><p>727</p><p>(574, 922)</p></td><td style="vertical-align:top"><p>174</p><p>(138, 219)</p></td><td style="vertical-align:top"><p>1159</p><p>(951, 1414)</p></td><td style="vertical-align:top"><p>259</p><p>(191, 352)</p></td><td style="vertical-align:top"><p>1033</p><p>(755, 1415)</p></td></tr><tr><td style="vertical-align:bottom"><p>7F</p></td><td style="vertical-align:top"><p>156</p><p>(132, 184)</p></td><td style="vertical-align:top"><p>378</p><p>(316, 452)</p></td><td style="vertical-align:top"><p>210</p><p>(175, 251)</p></td><td style="vertical-align:top"><p>555</p><p>(467, 661)</p></td><td style="vertical-align:top"><p>206</p><p>(164, 258)</p></td><td style="vertical-align:top"><p>346</p><p>(277, 432)</p></td></tr><tr><td style="vertical-align:bottom"><p>9V</p></td><td style="vertical-align:top"><p>203</p><p>(171, 241)</p></td><td style="vertical-align:top"><p>550</p><p>(454, 667)</p></td><td style="vertical-align:top"><p>339</p><p>(282, 408)</p></td><td style="vertical-align:top"><p>1085</p><p>(893, 1318)</p></td><td style="vertical-align:top"><p>352</p><p>(270, 459)</p></td><td style="vertical-align:top"><p>723</p><p>(558, 938)</p></td></tr><tr><td style="vertical-align:bottom"><p>14</p></td><td style="vertical-align:top"><p>212</p><p>(166, 270)</p></td><td style="vertical-align:top"><p>391</p><p>(315, 486)</p></td><td style="vertical-align:top"><p>282</p><p>(224, 356)</p></td><td style="vertical-align:top"><p>665</p><p>(554, 798)</p></td><td style="vertical-align:top"><p>336</p><p>(238, 473)</p></td><td style="vertical-align:top"><p>581</p><p>(434, 777)</p></td></tr><tr><td style="vertical-align:bottom"><p>18C</p></td><td style="vertical-align:top"><p>173</p><p>(137, 218)</p></td><td style="vertical-align:top"><p>552</p><p>(445, 684)</p></td><td style="vertical-align:top"><p>219</p><p>(177, 272)</p></td><td style="vertical-align:top"><p>846</p><p>(693, 1033)</p></td><td style="vertical-align:top"><p>278</p><p>(209, 369)</p></td><td style="vertical-align:top"><p>621</p><p>(470, 821)</p></td></tr><tr><td style="vertical-align:bottom"><p>19A</p></td><td style="vertical-align:top"><p>82</p><p>(66, 100)</p></td><td style="vertical-align:top"><p>239</p><p>(197, 288)</p></td><td style="vertical-align:top"><p>124</p><p>(100, 153)</p></td><td style="vertical-align:top"><p>365</p><p>(303, 440)</p></td><td style="vertical-align:top"><p>182</p><p>(141, 235)</p></td><td style="vertical-align:top"><p>341</p><p>(264, 439)</p></td></tr><tr><td style="vertical-align:bottom"><p>19F</p></td><td style="vertical-align:top"><p>61</p><p>(52, 71)</p></td><td style="vertical-align:top"><p>159</p><p>(131, 192)</p></td><td style="vertical-align:top"><p>89</p><p>(74, 107)</p></td><td style="vertical-align:top"><p>242</p><p>(199, 294)</p></td><td style="vertical-align:top"><p>120</p><p>(94, 154)</p></td><td style="vertical-align:top"><p>218</p><p>(168, 282)</p></td></tr><tr><td style="vertical-align:bottom"><p>23F</p></td><td style="vertical-align:top"><p>23</p><p>(18, 28)</p></td><td style="vertical-align:top"><p>152</p><p>(115, 199)</p></td><td style="vertical-align:top"><p>48</p><p>(37, 62)</p></td><td style="vertical-align:top"><p>450</p><p>(358, 566)</p></td><td style="vertical-align:top"><p>66</p><p>(46, 94)</p></td><td style="vertical-align:top"><p>293</p><p>(204, 420)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Additional Serotypes</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:top"><p>55</p><p>(45, 67)</p></td><td style="vertical-align:top"><p>212</p><p>(172, 261)</p></td><td style="vertical-align:top"><p>28</p><p>(24, 33)</p></td><td style="vertical-align:top"><p>603</p><p>(483, 753)</p></td><td style="vertical-align:top"><p>139</p><p>(99, 195)</p></td><td style="vertical-align:top"><p>294</p><p>(220, 392)</p></td></tr><tr><td style="vertical-align:bottom"><p>10A</p></td><td style="vertical-align:top"><p>212</p><p>(166, 269)</p></td><td style="vertical-align:top"><p>1012</p><p>(807, 1270)</p></td><td style="vertical-align:top"><p>141</p><p>(113, 177)</p></td><td style="vertical-align:top"><p>2005</p><p>(1586, 2536)</p></td><td style="vertical-align:top"><p>400</p><p>(281, 568)</p></td><td style="vertical-align:top"><p>1580</p><p>(1176, 2124)</p></td></tr><tr><td style="vertical-align:bottom"><p>11A</p></td><td style="vertical-align:top"><p>510</p><p>(396, 656)</p></td><td style="vertical-align:top"><p>1473</p><p>(1192, 1820)</p></td><td style="vertical-align:top"><p>269</p><p>(211, 343)</p></td><td style="vertical-align:top"><p>1908</p><p>(1541, 2362)</p></td><td style="vertical-align:top"><p>550</p><p>(386, 785)</p></td><td style="vertical-align:top"><p>1567</p><p>(1141, 2151)</p></td></tr><tr><td style="vertical-align:bottom"><p>12F</p></td><td style="vertical-align:top"><p>147</p><p>(112, 193)</p></td><td style="vertical-align:top"><p>1054</p><p>(822, 1353)</p></td><td style="vertical-align:top"><p>53</p><p>(43, 65)</p></td><td style="vertical-align:top"><p>1763</p><p>(1372, 2267)</p></td><td style="vertical-align:top"><p>368</p><p>(236, 573)</p></td><td style="vertical-align:top"><p>1401</p><p>(1002, 1960)</p></td></tr><tr><td style="vertical-align:bottom"><p>15B</p></td><td style="vertical-align:top"><p>140</p><p>(104, 189)</p></td><td style="vertical-align:top"><p>647</p><p>(491, 853)</p></td><td style="vertical-align:top"><p>74</p><p>(56, 98)</p></td><td style="vertical-align:top"><p>1480</p><p>(1093, 2003)</p></td><td style="vertical-align:top"><p>190</p><p>(124, 291)</p></td><td style="vertical-align:top"><p>1067</p><p>(721, 1578)</p></td></tr><tr><td style="vertical-align:bottom"><p>22F</p></td><td style="vertical-align:top"><p>167</p><p>(122, 230)</p></td><td style="vertical-align:top"><p>1773</p><p>(1355, 2320)</p></td><td style="vertical-align:top"><p>60</p><p>(45, 82)</p></td><td style="vertical-align:top"><p>4157</p><p>(3244, 5326)</p></td><td style="vertical-align:top"><p>286</p><p>(180, 456)</p></td><td style="vertical-align:top"><p>2718</p><p>(1978, 3733)</p></td></tr><tr><td style="vertical-align:bottom"><p>33F</p></td><td style="vertical-align:top"><p>1129</p><p>(936, 1362)</p></td><td style="vertical-align:top"><p>2026</p><p>(1684, 2437)</p></td><td style="vertical-align:top"><p>606</p><p>(507, 723)</p></td><td style="vertical-align:top"><p>3175</p><p>(2579, 3908)</p></td><td style="vertical-align:top"><p>1353</p><p>(1037, 1765)</p></td><td style="vertical-align:top"><p>2183</p><p>(1639, 2908)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Abbreviations: CI = confidence interval; GMT = geometric mean titre; LLOQ = lower limit of quantitation; N&nbsp;=&nbsp;number of participants; OPA&nbsp;=&nbsp;opsonophagocytic activity; PPSV23&nbsp;=&nbsp;pneumococcal polysaccharide vaccine (23-valent).</p><p>a.&nbsp;&nbsp; Study 1006 was conducted in the United States and in Sweden.</p><p>b.&nbsp;&nbsp; Assay results below the LLOQ were set to 0.5 &times; LLOQ in the analysis.</p><p>c.&nbsp;&nbsp; Evaluable immunogenicity population.</p><p>d.&nbsp;&nbsp; Open‑label administration of Prevenar&nbsp;20.</p><p>e.&nbsp;&nbsp; 2-sided CIs based on the Student t distribution.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Immune</u><u> responses in special populations</u></p><p>&nbsp;</p><p>Individuals with the conditions described below have an increased risk of pneumococcal disease.</p><p>&nbsp;</p><p>Studies in individuals with SCD, HIV, and HSCT have not been conducted with Prevenar&nbsp;20.</p><p>&nbsp;</p><p>Experience from clinical studies with Prevenar 13 (a pneumococcal conjugate vaccine consisting of 13 polysaccharide conjugates that are also in Prevenar&nbsp;20) are available in children and adults at higher risk of pneumococcal infection including immunocompromised children and adults with HIV infection or HSCT, and children with SCD.</p><p>&nbsp;</p><p>Participants who were healthy, or with stable non-immunocompromising chronic medical conditions, in all the age groups analysed had a lower immune response with Prevenar&nbsp;20 compared with Prevenar&nbsp;13 in spite of meeting the predefined non-inferiority margins. The clinical relevance of this observation is unknown.</p><p>&nbsp;</p><p><em>Sickle cell disease (SCD)</em></p><p>&nbsp;</p><p>An open-label single-arm study with 2&nbsp;doses of Prevenar&nbsp;13 given 6 months apart was conducted in 158 children and adolescents 6 to &lt;&nbsp;18&nbsp;years of age with SCD who were previously vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine at least 6 months prior to enrollment. After the first vaccination, Prevenar&nbsp;13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared with levels prior to vaccination. After the second dose, immune responses were comparable to those after the first dose. One year after the second dose, antibody levels measured by both IgG GMCs and OPA GMTs were higher than levels prior to the first dose of Prevenar&nbsp;13, except for the IgG GMCs for serotypes 3 and 5 that were numerically similar.</p><p>&nbsp;</p><p><em>HIV infection</em></p><p><em><u>&nbsp;</u></em></p><p><em><u>Children and adults not previously vaccinated with a pneumococcal vaccine</u></em></p><p>In Study 6115A1-3002 (B1851021), 151 participants 6 to &lt;&nbsp;18 years of age and 152 participants &ge;&nbsp;18&nbsp;years of age infected with HIV (CD4 &ge;&nbsp;200&nbsp;cells/&micro;L, viral load &lt;&nbsp;50,000&nbsp;copies/mL and free of active acquired immunodeficiency syndrome [AIDS]-related illness) not previously vaccinated with a pneumococcal vaccine were enrolled to receive 3&nbsp;doses of Prevenar&nbsp;13. As per the general recommendations, a single dose of PPSV23 was subsequently administered. The vaccines were administered at 1‑month intervals. Immune responses were assessed in 128 to 133 evaluable participants 6 to &lt;&nbsp;18 years of age and in 131 to 137 evaluable participants &ge;&nbsp;18&nbsp;years of age approximately 1&nbsp;month after each dose of the vaccine. After the first dose, Prevenar&nbsp;13 elicited antibody levels, measured by IgGGMCs and OPA GMTs, that were statistically significantly higher compared with levels prior to vaccination. After the second and third dose of Prevenar&nbsp;13, immune responses were similar to or higher than those after the first dose.</p><p><sup>&nbsp;</sup></p><p><em><u>Adults previously vaccinated with PPSV23</u></em></p><p>In Study 6115A1-3017 (B1851028), immune responses were assessed in 329 HIV-infected participants &ge;&nbsp;18&nbsp;years of age (CD4+ T-cell count &ge;&nbsp;200 cells/&micro;L and viral load &lt;&nbsp;50,000&nbsp;copies/mL) previously vaccinated with PPSV23 administered at least 6&nbsp;months prior to enrollment. Participants received 3 doses of Prevenar&nbsp;13: at enrollment, 6&nbsp;months, and 12&nbsp;months after the first dose of Prevenar&nbsp;13. After the first vaccination, Prevenar&nbsp;13 elicited antibody levels measured by IgG GMCs and OPA GMTs that were statistically significantly higher compared with levels prior to vaccination. After the second and third dose of Prevenar&nbsp;13, immune responses were comparable to or higher than those after the first dose. Participants who received previously 2 or more doses of PPSV23 showed a similar immune response compared to participants who previously received a single dose.</p><p><u>&nbsp;</u></p><p><em><u>Haematopoietic stem cell transplant (HSCT)</u></em></p><p>&nbsp;</p><p>In Study 6115A1-3003 (B1851022), 61 participants 2 to &lt;&nbsp;18 years of age and 190 participants &ge;&nbsp;18&nbsp;years of age with an allogeneic HSCT were enrolled to receive 3 doses of Prevenar&nbsp;13 with an interval of at least 1&nbsp;month between doses. The first dose was administered at 3&nbsp;to&nbsp;6&nbsp;months after HSCT. A fourth (booster) dose of Prevenar&nbsp;13 was administered 6&nbsp;months after the third dose. As per the general recommendations, a single dose of PPSV23 was administered 1&nbsp;month after the fourth dose of Prevenar&nbsp;13. Immune responses, as measured by&nbsp;IgG&nbsp;GMCs, were assessed in 41 to 52&nbsp;evaluable participants 2 to &lt;&nbsp;18&nbsp;years of age and in&nbsp;127 to 159 evaluable participants &ge;&nbsp;18&nbsp;years of age approximately 1&nbsp;month after vaccination. Prevenar&nbsp;13 elicited increased antibody levels after each dose. Immune responses after the fourth dose of Prevenar&nbsp;13 were significantly increased for all serotypes compared with those after the third dose with the exception of serotype 3 in the 2 to &lt;&nbsp;18&nbsp;years age group. Overall, participants 2 to &lt;&nbsp;18&nbsp;years of age had generally higher serotype‑specific immune responses compared with those &ge;&nbsp;18&nbsp;years of age.</p><p>&nbsp;</p><p>This study demonstrated that 4 doses of Prevenar&nbsp;13 elicited serum IgG concentrations similar to those induced by a single dose in healthy participants of the same age group.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Prevenar&nbsp;20 in one or more subsets of the paediatric population for the condition of prevention of disease caused by <em>Streptococcus pneumoniae</em> (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p><p><em>Invasive pneumococcal disease (IPD)</em></p><p>&nbsp;</p><p>Vaccine effectiveness of Prevenar 13 against vaccine-serotype IPD was evaluated in the SpIDnet study, a multi-country enhanced IPD surveillance project in Europe. Based on data over a 6-year period (2012-2018) from 10 sites in 7 European countries using Prevenar 13, the effectiveness against IPD caused by serotypes in the vaccine among children &lt;&nbsp;5 years of age was 84.2% (95% CI, 79.0‑88.1) and 88.7% (95% CI, 81.7-92.7) in children receiving &ge;&nbsp;1 Prevenar 13 dose and a complete vaccination schedule, respectively.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data revealed no special hazard for humans based on conventional studies of repeated‑dose toxicity and reproduction and developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride</p><p>Succinic acid</p><p>Polysorbate 80</p><p>Water for injections</p><p>&nbsp;</p><p>For adjuvant, see section&nbsp;2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C to 8&nbsp;&deg;C). Pre-filled syringes should be stored in the refrigerator horizontally to minimise the resuspension time.</p><p>&nbsp;</p><p>Do not freeze. Discard if the vaccine has been frozen.</p><p>&nbsp;</p><p>From a microbiological point of view, once removed from the refrigerator, the vaccine should be used immediately.</p><p>&nbsp;</p><p>Stability data indicate that the vaccine is stable for 96&nbsp;hours when stored at temperatures from 8 &deg;C to 25 &deg;C, or 72&nbsp;hours when stored at temperatures from 0 &deg;C to 2 &deg;C. At the end of these time periods Prevenar&nbsp;20 should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5&nbsp;mL suspension for injection in pre-filled syringe (Type I glass) with a tip cap (synthetic isoprene/bromobutyl blend rubber) and a plunger stopper (chlorobutyl rubber).</p><p>&nbsp;</p><p>Pack sizes of 1, 10, and 50 pre-filled syringes, with or without needle.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During storage, a white deposit and clear supernatant may be observed in the pre-filled syringe containing the suspension. Pre-filled syringes should be stored horizontally to minimise the resuspension time.&nbsp;</p><p>&nbsp;</p><p><u>Preparation for administration </u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Step 1. Vaccine resuspension</strong></p><p>Hold the pre-filled syringe horizontally between the thumb and the forefinger and shake vigorously until the contents of the syringe are a homogeneous white suspension. Do not use the vaccine if it cannot be resuspended.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p><strong>Step 2. Visual inspection</strong></p><p>Visually inspect the vaccine for large particulate matter and discolouration prior to administration. Do not use if large particulate matter or discolouration is found. If the vaccine is not a homogeneous white suspension, repeat steps 1 and 2.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p><strong>Step 3. Remove syringe cap</strong></p><p>Remove the syringe cap from the Luer lock adapter by slowly turning the cap counter clockwise while holding the Luer lock adapter.</p><p>&nbsp;</p><p>Note: Care should be taken to ensure that the extended plunger rod is not depressed while removing the syringe cap.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Step 4. Attach a sterile needle</strong></p><p>Attach a needle appropriate for intramuscular administration to the pre-filled syringe by holding the Luer lock adapter and turning the needle clockwise.</p></td></tr></tbody></table><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Manufactured by
Pfizer Ireland Pharmaceuticals
Grange Castle Business Park, Dublin, Ireland
Packed & Released by
Pfizer Manufacturing Belgium NV
Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>